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Summary
Cerebral small vessel disease (SVD), characterized by pathological processes that aﬀect
structure and function of the brain microvasculature and result in subsequent damage of
the cerebral white and deep grey matter, is the main cause for long-term disability and
vascular dementia. Cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL), the most common form of monogenic SVD leading
to early-onset stroke and vascular dementia, is caused by mutations in the Notch3 trans-
membrane receptor. Accumulation and deposition of the extracellular domain of Notch3
(Notch3-ECD) in blood vessel walls are the earliest disease manifestations. However, the
underlying molecular pathomechanism is incompletely understood and speciﬁc treatment
options are not available. To study the aggregation behavior of Notch3 mutants we have
recently developed an in vitro aggregation assay based on recombinant Notch3-ECD frag-
ments and their detection by the single-molecule spectroscopy technique called scanning
for intensely ﬂuorescent targets (SIFT).
While the vast majority of CADASIL mutations alter the number of cysteine residues
within the Notch3-ECD, over the last years several mutations not involving a cysteine
have been reported to be associated with a CADASIL-like phenotype provoking a debate
about their clinical signiﬁcance. In the ﬁrst part of this work, the in vitro assay was applied
to study the pathogenic potential of ﬁve of these mutations. Three of them showed an
aggregation behavior similar to cysteine-aﬀecting mutations, a ﬁnding supported by the
typical CADASIL-like clinical appearance of the mutation carriers and we thus classiﬁed
them as pathogenic mutations. For the two other mutants the available clinical data had
been fragmentary and in agreement with that, no signiﬁcant aggregation potential was
observed, strongly suggesting that they represent apathogenic polymorphisms. Thus, our
in vitro assay oﬀers new insights into the Notch3 aggregation mechanism and may serve
as diagnostic tool determining the clinical relevance of cysteine-sparing mutations.
In the second part of this thesis, the in vitro assay was used to search for small-molecule
aggregation inhibitors. Several synthetic compounds of the diphenylpyrazole (DPP) class
as well as natural polyphenolic substances with antiaggregatory properties were identiﬁed.
They not only inhibited the de novo aggregation of mutant Notch3 but were also capable
of dissolving pre-formed aggregates. Some of the compounds were subsequently shown to
be also eﬀective in a novel cellular assay based on the accumulation of mutant Notch3 in
the extracellular matrix (ECM) of mouse embryonic ﬁbroblasts (MEF). With this study
on drug-mediated inhibition of Notch3 accumulation we have laid a basis for an anti-
aggregation therapy.
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Zusammenfassung
Zerebrale Mikroangiopathien sind die häuﬁgste Ursache für Langzeitbehinderung und
vaskuläre Demenz. Sie sind durch pathologische Prozesse charakterisiert, die die Struktur
und Funktion der Mikrovaskulatur im Gehirn beeinträchtigen und dadurch zu Schädi-
gungen der weißen und tiefen grauen Substanz führen. CADASIL (zerebrale autosomal-
dominante Arteriopathie mit subkortikalen Infarkten und Leukoenzephalopathie), die häu-
ﬁgste monogene Form zerebraler Mikroangiopathien, führt zu juvenilen Schlaganfällen und
vaskulärer Demenz und wird durch Mutationen im Notch3 Rezeptor verursacht. Frühestes
pathologisches Merkmal ist die Akkumulation und Ablagerung der extrazellulären Domäne
von Notch3 (Notch3-ECD) in den Wänden kleiner Blutgefäße. Allerdings ist bisher wenig
über den zu Grunde liegenden molekularen Pathomechanismus bekannt und spezielle Be-
handlungsmöglichkeiten sind nicht verfügbar. Um das Aggregationsverhalten von Notch3
Mutanten zu studieren, haben wir einen in vitro Aggregationsassay entwickelt, der auf
rekombinanten Notch3-ECD Fragmenten und ihrer Detektion mittels SIFT (scanning for
intensely ﬂuorescent targets) beruht, einer speziellen Einzelmolekülspektroskopietechnik.
Während die Mehrheit der CADASIL Mutationen die Anzahl der Cysteinreste in der
Notch3-ECD verändert, ist in den letzten Jahren mehrfach über Mutationen ohne Cys-
teinbeteiligung berichtet worden, die mit einem CADASIL-ähnlichen Phänotyp assoziiert
sind und über deren klinische Relevanz derzeit diskutiert wird. Im ersten Teil dieser Ar-
beit wurde der in vitro Assay zur Untersuchung des pathogenen Potentials von fünf dieser
Mutationen verwendet. Drei von ihnen zeigten ein ähnliches Aggregationspotential wie
klassische Cystein-Mutationen, ein Befund, der durch die typischen CADASIL Symptome
der Mutationsträger gestützt wird. Wir klassiﬁzieren sie daher als pathogene Mutationen.
Für die beiden anderen Mutanten, deren klinische Beschreibung lückenhaft war, konnte
dementsprechend kein signiﬁkantes Aggregationspotential beobachtet werden, so dass sie
wahrscheinlich apathogene Polymorphismen darstellen. Somit eröﬀnet unser in vitro As-
say neue Einblicke in den Notch3-Aggregationsmechanismus und könnte als diagnostische
Methode zur Bestimmung der klinischen Relevanz von Nicht-Cystein Mutationen einge-
setzt werden.
Im zweiten Teil dieser Arbeit wurde der in vitro Assay für die Suche nach kleinen Molekülen
mit aggregationsinhibierender Aktivität eingesetzt. Mehrere synthetische Substanzen aus
der Klasse der Diphenylpyrazole (DPP), sowie natürliche Polyphenole mit antiaggrega-
torischen Eigenschaften wurden identiﬁziert. Sie hemmten nicht nur die de novo Aggre-
gation von einer Notch3 Mutante, sie waren auch in der Lage, präformierte Aggregate
wieder aufzulösen. Für einige der Substanzen konnte anschließend auch eine Wirkung in
v
einem zellulären Assay gezeigt werden, der auf der Akkumulation einer Notch3 Mutante
in der extrazellulären Matrix (ECM) muriner embryonaler Fibroblasten (MEF) beruht.
Mit dieser Studie zur substanzvermittelten Hemmung der Notch3 Akkumulation haben
wir den Grundstein für eine Antiaggregationstherapie gelegt.
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1 Introduction
Stroke represents, after ischemic heart disease, the second leading cause of death with
6.7 million casualties worldwide in 2012.1 Thus, it is a major burden for public health.
Another huge impact on ﬁnancial costs to society is caused by dementia. Whereas in 2010
around 25.6 million people were aﬀected by dementia with worldwide costs of US $ 604
billion, the total number of cases in 2050 is projected to be about 115.4 million.2
Two main types of stroke can be distinguished (Figure 1.1): Haemorrhagic stroke and
ischemic stroke. Haemorrhagic stroke accounts for about 20 % of the cases and arises from
vessel wall rupture leading to extravasation of the blood into the surrounding tissue. In 80
% of the cases acute vessel occlusion or chronic hypoperfusion and subsequent depletion of
oxygen and nutrients in the surrounding tissue occurs resulting in ischemic stroke.3 The
main causes for ischemic stroke are large-artery atherosclerosis, cardioembolism and small
vessel disease (SVD).4 SVD is - although accounting for only 20 % of all stroke cases -
the main cause for long-term disability and vascular dementia, which represents the most
common form of cognitive impairment after Alzheimer’s dementia.5
Figure 1.1: Distribution of hemorrhagic (red) and ischemic (green) stroke in white
population. Ischemic stroke can be further subdivided into small vessel disease, cardioembolism,
large artery atherosclerosis and other rare causes (adapted from Warlow et al. 3)
1
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1.1 Cerebral small vessel disease
Cerebral SVD is characterized by pathological processes that aﬀect structure and function
of the brain microvasculature, including small arteries, perforating arterioles, capillaries
and small veins and the subsequent damage of the cerebral white and deep grey matter.5
Sporadic SVD normally remains unnoticed over years before becoming evident at higher
age with sudden-onset stroke symptoms as well as neurological symptoms such as cognitive
decline, dementia and depression.6
In contrast to large arteries, small arteries can not be visualized and investigated easily in
vivo.7 Thus, only the consequences of changes in the small vessel network, the parenchyma
lesions can be detected with neuroimaging and therefore serve as a marker of small vessel
disease.5 These changes manifest in small subcortical infarcts, lacunes, white matter hy-
perintensities, visible perivascular spaces, cerebral microbleeds and brain atrophy.6 Since
pathological data are mainly available from end-stage SVD patients little is known about
the pathogenesis and the earliest disease causing events. Histopathological characteristics
are mainly described as loss of vascular smooth muscle cells (vSMCs), thickening of the
vessel wall and narrowing of the lumen which can lead to reduced blood ﬂow.5 However,
it is still under debate how this correlates with the neurological and cognitive symptoms.6
Although risk factors such as age, hypertension, smoking, diabetes mellitus, atrial ﬁbrilla-
tion and obesity have been identiﬁed8, they account only for part of the disease risk9 and
other factors including genetics may be pivotal.
Besides the sporadic form of SVD, several monogenic forms have been identiﬁed that share
the main clinical and pathological features of the disorder (Table 1.1 ). They include cere-
bral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy
(CARASIL), retinal vasculopathy with cerebral leukodystrophy (RVCL), Collagen type
IV-related SVD and cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL).10,11 Table 1.1 depicts the characteristic clinical
features and aﬀected genes for these inheritable forms of SVD. Due to their deﬁned ge-
netic etiology and early onset of the clinical symptoms, the monogenic SVD forms serve
as valuable models to study vascular changes and biological pathways that ﬁnally lead to
vascular dementia.
In this work we focus on CADASIL, the most common monogenic SVD. Although abun-
dant clinical data are available, there is still a lack in the knowledge of the molecular
pathomechanism and also speciﬁc treatment options are missing. Identifying details of
the initiation factors as well as the examination of the progression of this disease may not
only help to ﬁnd a cure, but also to advance our understanding of sporadic SVD.
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Table 1.1: Monogenic cerebral small vessel diseases. CADASIL: cerebral autosomal dom-
inant arteriopathy with subcortical infarcts and leukoencephalopathy, CARASIL: cerebral auto-
somal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, RVCL: retinal
vasculopathy with cerebral leukodystrophy, COL4: collagen type IV
Disorder Aﬀected gene Characteristic clinical features
CADASIL NOTCH3 migraine with aura, subcortical infarcts,
(autosomal dominant) mood disturbance, apathy, cognitive impairment
CARASIL HTRA1 recurrent small strokes, alopecia,
(autosomal recessive) kyphosis, spondylosis
RVCL TREX1 retinal vasculopathy, strokes, cognitive
(autosomal dominant) dysfunction, headaches, personality disorders
COL4- COL4A1/A2 ischemic stroke, intracerebral haemorrhages,
related (autosomal dominant) migraines with/without aura, dementia
disorders
1.2 CADASIL
Starting in the 1970’s ﬁrst descriptions of European families suﬀering from a vascular
dementing disease appeared in the literature. The disease was described with similar
pathological ﬁndings, but the name varied from chronic familial vascular encephalopa-
thy12, hereditary multi-infarct dementia13,14, autosomal dominant syndrome with stroke-
like episodes and leukoencephalopathy15 to a familial disorder with subcortical ischemic
strokes, dementia, and leukoencephalopathy16. In 1993, Tournier-Lasserve et al. 17 linked
the disease to chromosome 19 and created the acronym CADASIL, Cerebral Autosomal
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy depicting
the main characteristics of the disease. The same group identiﬁed NOTCH3 as the de-
fective gene10 and described the stereotypic mutations in detail three years later.18 Until
today over 200 diﬀerent CADASIL mutations have been identiﬁed. The disease prevalence
is estimated to be about 4 per 100 000.11
The neurological and neuropsychological symptoms in CADASIL patients can appear iso-
lated but develop successively in general with some variances in onset and duration (Figure
1.2). Although there is a high heterogeneity in clinical appearance between and also within
families, the disease can be characterized by four principle symptoms: migraine with aura,
subcortical ischemic events, mood disturbances/apathy and cognitive impairment.11 The
ﬁrst manifestation in young CADASIL patients is primarily migraine with aura19,20, but
3
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since this symptom occurs in other neurological conditions as well, CADASIL is diagnosed
often after the ﬁrst ischemic episode occuring on average with 51 years.21 Importantly, cog-
nitive decline is already observed before the ﬁrst ischemic strokes.22 CADASIL progresses
slowly with exacerbations of the symptoms. During the course of the disease cognitive and
motoric abilities decline due to recurrent strokes leading to deﬁcits in episodic memory,
attention, executive and visuospatial functions together with psychomotor slowing and a
narrowing of the ﬁeld of interest.23 The infarcts are located in the white matter or basal
ganglia as well as in the brain stem, whereas the cerebral cortex is well preserved.24,25
Finally, by the age of 65, 80 % of CADASIL patients are demented.26 Death occurs within
a mean period of 23 years after onset of the disease.26
Figure 1.2: Time axis of the main clinical manifestations of CADASIL. The earliest
appearance of magnetic resonance imaging (MRI) white matter abnormalities is unknown (dotted
line) Adapted from Chabriat et al. 11
Changes in the brain parenchyma of CADASIL patients can be detected by cranial MRI.
Increased signals on T2-weighted or ﬂuid-attenuated inversion recovery images represent
white matter abnormalities, that normally precede the onset of other symptoms by 10-15
years.11 These white matter hyperintensities (WMH) can also be observed in asymp-
tomatic patients carrying the mutated gene and may be associated with axonal demyeli-
nation.27 Since periventricular WMH regions are very common in CADASIL patients with
a prevalence of 96 % , their absence almost excludes the diagnosis.27 Furthermore, lacunar
lesions, subcortical infarcts and microstructural tissue alterations that ﬁnally lead to corti-
cal thinning and brain atrophy characterize the etiopathology of CADASIL patients.28–31
MRI observations have a high diagnostic value on a macroscopic level, but typical
CADASIL abnormalities can also be detected by microscopic and ultrastructural inves-
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tigations. Histological stainings of post-mortem brains show a loss of vSMCs32,33 and a
thickening of the walls of small and medium-sized leptomeningeal and penetrating arteries
in the white matter resulting in lumen stenosis.25,33 This non-arteriosclerotic ﬁbrosis may
be due to accumulation of extracellular matrix (ECM) proteins, such as ﬁbronectin and
type I collagen24,25,34 as well as deposition of degenerated vSMCs debris.25,33 These mor-
phological changes share CADASIL patients with patients suﬀering from sporadic SVD.
Although the symptoms are exclusively neurological, CADASIL is a systemic arteriopa-
thy, since vascular changes can also be found in other organs, for example in skin and
muscle, providing histological diagnosis options.35,36 Apart from the thickening of arterial
walls (Figure 1.3 A), the presence of granular osmiophilic material (GOM) is an invariant
hallmark of CADASIL (Figure 1.3 B). GOM, a granular electron-dense extracellular ma-
terial, can be found typically close to the surface of vSMCs, varying in size between 0.2
to 0.8 m and is composed of 10 to 15 nm granules.24,35,36 These deposits are negative
for histological stainings with Congo red, thioﬂavin and other markers of cerebrovascular
diseases24,37 and have, on the other hand, not been detected in other diseases.36
Control CADASIL
Granular osmiophilic
material (GOM)
A B
Figure 1.3: Appearance of arterial changes in CADASIL. A) Paraﬃn-embedded brain
sections of a healthy control and a CADASIL patient were stained for ﬁbronectin, counterstained
with hematoxylin and analyzed by bright-ﬁeld microscopy. Brain vessel of CADASIL patient shows
characteristic thickening of the vessel wall. Adapted from Kast et al. 34 B) Electron micrograph
of a dermal artery showing deposits of GOM (arrows) at the surface of vSMCs (S). Adapted from
Kalimo et al. 25
Despite of all the diagnostic tools developed over the years, there is still a lack in eﬀec-
tive treatment of CADASIL. Until now there is no curative therapy for CADASIL, only
symptoms can be medicated. Forteza et al. 38 published in 2001 that acetazolamide can
alleviate the symptoms of migraine with aura in CADASIL patients. Furthermore, Dich-
gans et al. 39 observed a improvement in executive functions of patients treated with the
cholinesterase inhibitor donepezil, although the results were not signiﬁcant. Peters et al. 40
on the other hand described that the administration of L-arginine induces increased cere-
bral vasoreactivity in CADASIL patients, thus suggesting it as a possible substance for
therapeutic treatment.
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1.3 The Notch3 Receptor
1.3.1 Structure and Function
Joutel et al. 10 identiﬁed in 1996 NOTCH3 on chromosome 19p13 as the mutated gene
underlying the CADASIL pathology. The human NOTCH3 gene encompasses 41.3 kilo-
bases containing 33 exons. It encodes the 280 kDa (2321 amino-acids) single-pass type I
transmembrane receptor Notch3 which belongs to the family of Notch proteins conserved
from worms to man. Notch signaling between neighboring cells plays an important role in
cell type diﬀerentiation and organogenesis.41
The four mammalian isoforms of Notch are highly homologous and share the same domain
structure. Notch3 consists of a large extracellular domain (ECD) containing 34 epidermal
growth factor (EGF)-like repeats, three cysteine-rich lin12/notch repeats (LNR), a trans-
membrane domain and an intracellular domain (ICD) with seven ankyrin repeats ﬂanked
by two nuclear localization signals and a PEST motif (Figure 1.4).
Ca2+
ECD ICDTM
S1 S2 S3
LRS
EGF-like 
repeats
LNR
Ankyrin
repeats
PEST motif
Figure 1.4: Notch3 structure. The heterodimer is built up of an ECD comprising 34 EGF-like
repeats and three cysteine-rich LNR repeats including the ligand recognition site (LRS) on EGF-
like repeats 10/11. After the transmembrane domain (TM), an ICD follows with seven ankyrin
repeats and a PEST motif. Arrows indicate the three cleavage sites S1-3.
The protein is synthesized as a 280 kDa precursor which undergoes in total three pro-
teolytic cleavages (S1-S3) during maturation and signaling. The S1 cleavage occurs in
the Golgi complex by a furin-like convertase generating a non-covalently associated het-
erodimer which is subsequently inserted into the plasma membrane.42 S2 and S3 cleav-
ages are initiated during signaling. Membrane-bound ligands (e.g. Delta or Serrate) from
neighboring cells interact with the ligand binding domain in the Notch EGF-like repeats
10/11 leading to the extracellular S2 cleavage by an ADAM family metalloprotease, the
TNF-converting enzyme (TACE) close to the transmembrane domain.43 The ECD is
shedded and the truncated receptor becomes susceptible for S3 cleavage by -secretase,
an unusual protease complex cleaving within the plasma membrane.44 This results in the
release of the ICD into the cytosol, its translocation to the nucleus and association with
DNA-binding transcriptional regulators like RBP-J to activate target genes.45 In the
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extracellular space the ligand-Notch3 ECD complex is internalized by the signaling cell,
followed by recycling of the ligand and degradation of Notch3 ECD.46
Mutations in various members of the Notch signaling pathways cause developmental dis-
eases aﬀecting diﬀerent human organs.47 In contrast, CADASIL is an adult-onset disease.
Notch3 is mainly expressed in mural cells (vSMCs, pericytes) of the vasculature48 and
studies on Notch3 knockout (Notch3 -/-) mice demonstrated that Notch3 is non-essential
for survival, since the mice are viable and fertile. However, structural defects of arteries
in adult mice, compromised arterial pressure and cerebral blood ﬂow (CBF), as well as
the abnormal shape of adult vSMCs demonstrate, that Notch3 is an essential regulator of
arterial diﬀerentiation and maturation.49–51
1.3.2 Classical Notch3 mutations
In over 500 families more than 200 mutations have been reported, all of them located
in exons 2-24 out of the 33 exons of NOTCH3.11 These exons encode for the 34 EGF-
like repeats of the ECD, each of which contains six highly conserved cysteine residues.
These form three disulﬁde bridges between cysteines 1 and 3, 2 and 4 and 5 and 6 (Figure
1.5 A) which are essential for the 3D structure of each EGF-like repeat.52 95 % of the
CADASIL-linked mutations are missense mutations, only few are in-frame deletions or
splice-site mutations, but almost all mutations lead to an odd number of cysteines either
by gain or loss of one cysteine (Figure 1.5 B).11 Containing over 85 % of the mutations, the
mutational hotspot can be found within EGF-like repeats 2 to 6 (Figure 1.6).53 Until now,
genetic screening for mutations in the NOTCH3 gene is with almost 100 % sensitivity as
well as 100 % speciﬁcity the gold standard for the CADASIL diagnosis.53–55
C1 C2
C3
C4 C5
C6
N
... C
EGF-like repeat
WT
CADASIL
missense
mutations
A B
Figure 1.5: Schematic drawings of an EGF-like repeat and typical CADASIL muta-
tions. A) Six highly conserved cysteine residues form three disulﬁde bridges (red) between C1-C3,
C2-C4 and C5-C6. B) Typical CADASIL missense mutations lead to an odd number of cysteines
either due to an additional one (red dot) or a lack of one. Adapted from Chabriat et al. 11
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A variety of in vitro and mouse studies revealed that Notch3 mutations typically neither
inﬂuence receptor maturation nor ligand binding and activate the signaling cascade eﬃ-
ciently.55–60 Together with the fact that the loss of Notch3 in Notch3 -/- mice does not lead
to the typical CADASIL pathology, this suggests that loss of function is not the prevalent
pathogenic mechanism of CADASIL mutations. This hypothesis is also supported by data
from diﬀerent mouse models expressing mutated Notch3.61–64 Taken all the data together,
Joutel 65 suggested that a neomorphic toxic mechanism for mutant Notch3 rather than
compromised canonical Notch3 function is the main cause for CADASIL.
Figure 1.6: Distribution of Notch3 mutations in EGF-like repeats 1-34. A) Number of
diﬀerent mutations found in the EGF-repeats of extracellular domain of Notch3 (Notch3-ECD).
B) Mutations and polymorphisms used in this work.
Joutel et al. 48 revealed that the S2 cleavage product, the 210 kDa Notch3-ECD, accumu-
lates in the vSMC layer of vessel walls (Figure 1.7). Ishiko et al. 66 conﬁrmed that the
Notch3-ECD is one component of the GOM deposits. Data from patients reveal that the
accumulation of Notch3 and the presence of GOM deposits are the earliest manifestations
of CADASIL, already preceding the ﬁrst symptoms.67,68 These data are supported by
experiments using a transgenic mouse model with a CADASIL-causing Notch3 point mu-
tation that leads to the main pathological features of the disease including Notch3-ECD
accumulation, followed by GOM deposits and later also to progressive white matter dam-
age and reduced CBF.63 This transgenic mouse thus serves as an early disease model and
together with the patient data reveals the accumulation of Notch3-ECD as one of the ﬁrst
key features of CADASIL.
Thus, CADASIL can be considered a protein misfolding disease with dementia as ﬁnal
consequence. In this respect it resembles a variety of human diseases characterized by
either extracellular or intracellular accumulation and deposition of insoluble aberrant or
misfolded proteins. The most common ones are Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington disease (HD), Creutzfeldt-Jakob disease (CJD) and frontotem-
poral dementia (FTD). In contrast to CADASIL, the deposits found in these diseases
(also called amyloidoses) contain mainly ﬁbrillar material rich in -sheet structures and
8
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therefore bind to the histochemical dye Congo red, which, combined with polarized light,
makes the protein appear green.
Control CADASIL CADASIL
Figure 1.7: Accumulation of Notch3-ECD in the vessel wall. Left and middle: Paraﬃn-
embedded brain sections of a healthy control and a CADASIL patient were stained for Notch3,
counterstained with hematoxylin and analyzed by bright-ﬁeld microscopy. Right: Frozen brain
section of a CADASIL patient stained for Notch3 and analyzed by confocal ﬂuorescent microscopy.
Adapted from Kast et al. 34
So far, the molecular mechanism underlying the aggregation of Notch3-ECD is still un-
known. Already in 1997 Joutel et al. 18 hypothesized that aberrant dimerisation of the
unpaired cysteine residues of two Notch3 proteins or with another cysteine-containing
protein may lead to the accumulation of Notch3-ECD. This was conﬁrmed by modeling
the 3D structures of the ﬁrst six EGF-like domains oﬀering two potential pathomecha-
nisms: 1) domain misfolding due to disulﬁde bridge reorganisation and 2) unphysiological
intermolecular disulﬁde bridge formation.69 Our group has developed an in vitro assay and
demonstrated that aggregation of mutant proteins is triggered by their unpaired sulfhydryl
groups.70 We further obtained data from the analysis of a truncated puriﬁed Notch3-ECD
fragment containing the ﬁrst ﬁve EGF-like domains and showed that in contrast to wild-
type (wt) protein CADASIL-mutant Notch3 is able to aggregate in vitro.71 Furthermore,
we revealed that mutant Notch3 is able to sequester wt Notch3 as well as other proteins
such as thrombospondin 2 (TSP-2) into the aggregates. Another study identiﬁed latent
TGF- binding protein (LTBP-1) as major interactor of mutant Notch3, once more arguing
for a neomorphic eﬀect of the Notch3 mutations.34 Our ﬁnding that Notch3 aggregates can
be dissolved in SDS-buﬀer only in presence of a reducing agent such as -mercaptoethanol
(-ME), substantiated the existing data that mutant Notch3 aggregates are cross-linked
by disulﬁde bonds.71,72
1.3.3 Atypical (cysteine-sparing) Notch3 mutations
Although typical CADASIL mutations alter the number of cysteines, over the last years
diﬀerent mutations not involving a cysteine residue have been reported to be associated
with a CADASIL-like phenotype. Their relevance for the disease progress is still con-
troversially discussed. So far it is not clear, whether these mutations are rare missense
9
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polymorphisms or deleterious variants.73 Due to the lack of appropriate approaches the
pathogenicity of these variants could so far not be studied experimentally.
At the beginning of this thesis eight mutations that do not alter the number of cysteines
had been reported, ﬁve of them located within the EGF repeats 1-5 (Table 1.2).74–85 The
mutation R61W which substitutes a basic amino acid with an aromatic amino acid was
found in an American patient suspected with CADASIL. In this case NOTCH3 exons
1-33 were sequenced and skin biopsies displayed GOM deposits.82 The R75P mutation
introducing a bulky proline instead of the basic arginine residue is the best character-
ized cysteine-sparing mutation so far occurring in Japanese, Chinese and Korean pa-
tients.77–79,83,84 Depending on the case report nearly all relevant exons were sequenced
and also skin biopsies indicated the presence of classical GOM deposits. In addition to
these point mutations the in-frame deletion ∆A88-G91 has been reported which results in
the loss of four consecutive amino acids altering the distance between two cysteines to just
one residue. This mutation was found in an Italian family, screened for exons 2-23 and
positive for GOM deposits.76 The conservative mutation R213K substituting one basic
amino acid with another was found in a Japanese autopsy case without information about
sequenced exons or GOM deposits.74,75 The mutations T577A and S978R were published
only in a short note without information about sequenced exons and presence of GOM.80
The mutation A1020P on the other hand was examined in more detail.81 Exons 2-24 were
sequenced and one patient also was diagnosed positive for Notch3 deposits by skin biopsy
and immunostaining. The other patient however had normal skin biopsy ﬁndings. The
mutation D80G with an amino acid exchange from acidic to aliphatic was identiﬁed in one
of our own CADASIL families.85 Sequencing the complete NOTCH3 gene revealed four
family members with a typical CADASIL clinical and imaging phenotype. Skin biopsy,
however, revealed GOM deposits in only one patient. The mutation was absent in a
healthy sibling.
The pathomechanism underlying cysteine-sparing mutations is unknown and their clinical
relevance intensively discussed. One possibility is that they also lead to protein misfolding
due to steric hindrances or polarity change of amino acids. This could also result in
aberrant disulﬁde bonding or may promote the aggregation process via another unknown
mechanism.
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1.4 Confocal single molecule spectroscopy
While many studies in the past have focused on the description of Notch3-ECD aggregates
in vivo, little is known about the molecular mechanisms underlying their formation. This
is primarily due to the lack of in vitro aggregation assays and methods to monitor it. Con-
focal single molecule spectroscopy techniques such as ﬂuorescence correlation spectroscopy
(FCS) were originally developed to study the behavior of single ﬂuorescent molecules in
solution. FCS can detect extremely low concentrated particle diﬀusing in aqueous buﬀer
solution with a stationary focus. This ﬂuctuation is reﬂected by the ﬂuorescent emission
of the molecules detected by avalanche photo diodes (APDs). The signal can be quanti-
ﬁed by mathematical procedures such as autocorrelation analysis. By this means diﬀerent
parameters of the investigated particles such as speciﬁc ﬂuorescent intensity, local con-
centration, lateral diﬀusion coeﬃcient and thus size of the molecule can be determined.
The theoretical concept of FCS was described in Schwille 88 and Schwille et al. 89 . In
biomedicine it was applied to the analysis of molecules at submicromolar concentrations
and used to examine the aggregation behavior of proteins such as -synuclein (-syn) and
prion protein (PrP) in vitro and to learn more about the molecular origins of neurodegen-
erative diseases associated with mutations in these proteins. Thus, FCS appeared to be
highly suited to study the features of the Notch3 aggregation process.
1.4.1 Scanning for intensely ﬂuorescent targets (SIFT)
In FCS diﬀusion time becomes a limiting factor as soon as large molecule at sub-picomolar
concentrations have to be detected. The probability of a molecule passing through the
focus within a reasonable measurement time decreases the larger it is and thus the slower
it diﬀuses. Thus, SIFT was developed which uses a scanning procedure instead of a
stationary focus to detect large molecules with low diﬀusion times. A mobile focus is used
that scans in a meander-like fashion through the sample volume (Figure 1.8). The scanning
allows a molecule detection in a femtomolar range, thus increasing the number of particles
passing through the focus by about 100-fold compared to the static measurements. As
the dwell time of a molecule in the focus is no longer determined by the diﬀusion time
but by the scanning speed of the laser beam , large targets can be recognized by intensity
analysis. With the intensity distribution the highly intensive signal of multiple labeled
large target molecules can be separated from the background signal. At the same time the
number of peaks should be proportional to the number of target molecules. The principle
of the SIFT technique was described in Bieschke et al. 90 and Giese et al. 91 .
The development of dual-color SIFT now allows a simultaneous measurement of two
molecules with diﬀerent ﬂuorescent properties in the same sample. The emitted photons
of the excited ﬂuorescent dyes are collected by the same objective and passed through the
ﬁrst dichroic mirror, where the signal is separated from the laser beam. The following
12
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Figure 1.8: Measurement setup of the Insight II Reader. Schematic picture of a two-
color FCS reader with scanning unit for SIFT measurements. Laser beam is focused through a
dichroic mirror and a water immersions objective into the sample. The sample with ﬂuorescently
labeled proteins of diﬀerent sizes is scanned. The emitted ﬂuorescent light passes through the same
objective and is directed by dichroic mirrors through the pinhole to the APDs.
pinhole with a diameter of 70 m blocks any ﬂuorescent light not originating from the
focal region, thus separating the signal from unspeciﬁc background. Finally, the emission
signals from the two ﬂuorophores are separated by a second dichroic mirror and detected
by two separate APDs (Figure 1.8). Thus, the signal of dual-color molecules can be de-
tected in both detection channels and analyzed in a two-dimensional histogram (Figure
1.9). This enables for example the separation of the dual-color signal of the target aggre-
gates from any mono-color signals generated during puriﬁcation and labeling procedures.
On the other hand, interaction behavior of two diﬀerent target molecules can be studied
as well.
1.4.2 Analysis of Notch3 aggregation by SIFT
SIFT was successfully used to study the aggregation process of -syn and PrP.92 We
therefore have applied it to study the aggregation behavior of Notch3 mutants identiﬁed
in CADASIL patients. First attempts with cell lysates containing overexpressed Notch3-
ECD indicated enhanced multimer formation of CADASIL-mutated constructs, however
multimer formation could be also detected in wt Notch3-ECD.70 We improved the assay
by using puriﬁed Notch3 protein. To ensure correct folding and posttranslational mod-
iﬁcation, we obtained it from the supernatant of transiently transfected cultured cells.
Since secretion of the complete Notch3-ECD is very ineﬃcient due to complicated fold-
ing of its 34 EGF-like domains, we used a Notch3 fragment containing EGF-like repeats
13
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Figure 1.9: SIFT intensity histogram. A) 2D histogram depicts the intensity of the photon
counts in the green (Alexa 488) channel (x-axis) and the red (Alexa 647) channel (y-axis). The
plot is divided into 9 equal segments. Low intensity signals are excluded by setting a threshold.
B) Distribution of detected proteins in the 2D histogram. Monomers are located in the lower left
corner. Higher order multimers of one color are aligned along the axes and dual-color multimers
are located in the white area of the histogram.
1− 5 (Notch3-EGF1−5), the mutational hotspot harbouring 70 % of all known CADASIL
mutations53, which is secreted very eﬃciently.71 Puriﬁed His-tagged Notch3-EGF1−5 was
obtained by metal ion aﬃnity chromatography. With the puriﬁed protein we could show
that CADASIL-mutant but not wt Notch3-EGF1−5 spontaneously form multimers. Fur-
thermore, experiments with -ME and bismaleimide, a crosslinker speciﬁc for sulfhydryl
groups, could demonstrate the involvement of cysteine residues and thus sulfhydryl groups
in the aggregate formation. We could further show that mutant Notch3-EGF1−5 sponta-
neously co-aggregates with TSP-2 as well as with LTBP-1.34,71
14
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1.5 Aim of this work
The aggregation of the Notch3-ECD triggered by mutations is considered the key deter-
minant of CADASIL pathogenesis and our establishment of an in vitro aggregation assay
has turned out to represent an important advancement in the ﬁeld. The procedure used
so far for the puriﬁcation of Notch3 fragments required for this assay relies on a metal
ion aﬃnity matrix binding to a His-tag and the elution by EDTA. The drawbacks of this
method were the tedious removal of the EDTA, the presence of the His-tag on the puriﬁed
protein and the suboptimal purity. Therefore, the ﬁrst aim of this thesis was to improve
the protein puriﬁcation procedure by establishing a new system based on the HaloTag
technology which allows covalent binding of the target protein to a puriﬁcation matrix
and subsequent proteolytic removal of the aﬃnity tag.
The second goal was to apply the improved method to the analysis of the aggregation
behavior of cysteine-sparing Notch3 variants. Some of them have been reported to cause
CADASIL, but their pathogenic potential and clinical relevance is currently under debate.
The third goal of this thesis was to identify small molecule aggregation inhibitors. A
number of synthetic and natural compounds were screened in the in vitro assay. Some
of the substances with signiﬁcant eﬃciency were further tested in a cellular assay using
mouse embryonic ﬁbroblasts (MEFs) transfected with Notch3-EGF1−5 fragments.
15

2 Results
2.1 HaloTag-mediated puriﬁcation of Notch3 fragments
Using SIFT we have developed an in vitro assay to study details of the aggregation process
triggered by mutations in the Notch3-ECD (see section 1.4). This assay relies on the
availability of highly puriﬁed and correctly folded proteins which can be obtained from
conditioned supernatant of transiently transfected cultured cells. Since our earlier studies
had revealed ineﬃcient secretion of the full ECD or versions containing the ﬁrst 10 or 15
EGF-like repeats, we had chosen a Notch3-ECD fragment consisting of the signal peptide
and EGF-like repeats 1− 5 encompassing the mutational hotspot of CADASIL (Figure
1.6).71 Puriﬁcation from cell culture supernatants had so far been performed by a metal
ion aﬃnity puriﬁcation approach making use of the C-terminal His tag attached to Notch3-
EGF1−5. However, this approach suﬀered from several drawbacks including elution from
the matrix by EDTA (which had to be removed by an additional dialysis step), suboptimal
purity and yield and the inability to remove the aﬃnity tag. To overcome these limitations,
we investigated whether HaloTag-mediated puriﬁcation93 could be used as alternative
procedure.
2.1.1 The Halo aﬃnity tag
The HaloTag protein is a mutated form of the dhaA hydrolase that can form a stable
covalent bond with immobilized chloroalkane substrates enabling an eﬃcient and speciﬁc
capture of proteins expressed as HaloTag fusion proteins.93 To examine its suitability for
purifying Notch3-EGF1−5 fragments we fused it to the C-terminus of our target protein
and used it for aﬃnity puriﬁcation (Figure 2.1). Conditioned medium was dialyzed and
secreted fusion protein was bound covalently to the HaloLink resin. In contrast to metal
aﬃnity matrices the HaloLink resin shows low nonspeciﬁc binding and impurities can be
eﬃciently removed by stringent washing. The target protein is released by tobacco etch
virus (TEV) protease, recognizing a speciﬁc cleavage site located between both proteins,
while the HaloTag protein remains bound to the resin. Subsequently, the TEV protease is
removed via its His-tag using HisLink resin yielding highly puriﬁed tag-free target protein.
17
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Figure 2.1: Scheme of the HaloTag puriﬁcation. Conditioned medium from HEK293E cells
transiently transfected with the HaloTag fusion protein was collected and dialyzed. The fusion
protein binds covalently to HaloLink resin via the HaloTag. After stringent washing the target
protein was released from the HaloTag bound to the resin by cleaving of TEV protease. TEV
protease was removed by binding to HisLink resin via its His-tag. The tag-free target protein was
recovered in PBS.
2.1.2 Overexpression and secretion of Notch3-EGF1−5
Since the molecular size of the HaloTag protein (33 kDa) diﬀers substantially from the
previously used myc-His tag, expression and secretion conditions had to be reestablished.
We, therefore tested two diﬀerent expression vector systems: one using the standard vector
available with the HaloTag puriﬁcation system (pFC14A) and one using the previously
used pTT5 vector. After cloning the Notch3-EGF1−5 insert into the pFC14A vector,
it is expressed from the cytomegalovirus (CMV) promotor as fusion protein with a C-
18
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terminal HaloTag. For expression from the pTT5 vector which contains an improved CMV
expression cassette optimized for protein expression in HEK293E cells94 we replaced the
previously used myc-His tag with the HaloTag sequence (Figure 2.2).
M M M LLL
pTT5
myc-His
pTT5
Halo
pFC14A
Halo
Notch3-EGF1-5 Halo
Notch3-EGF1-5 myc-His 25
37
50
kDa
A
B
Notch3 EGF 1-5 (234 aa)
TEV 
site (7 aa)
myc His
tag (21 aa)
28 kDa
62 kDa
Figure 2.2: Expression analysis of wt Notch3-EGF1−5. A) Schematic illustration of both
Notch3-EGF1−5 fusion proteins with myc-His tag and HaloTag respectively. Notch3-EGF1−5 myc-
His contains the myc tag of 15 amino acids with six histidines fused to the C-terminus of Notch3-
EGF1−5. Notch3-EGF1−5 Halo contains a HaloTag linked with a TEV recognition site to the
C-terminus of Notch3-EGF1−5. B) HEK293E cells were transiently transfected with the original
myc-His-tagged version in the pTT5 vector and the two Halo-tagged versions in the pTT5 and
pFC14A vector. Cells were harvested after three days. Amount of expressed Notch3-EGF1−5 in
conditioned medium (M) and cell lysate (L) is determined by Western Blotting under reducing
conditions. 2 g of cellular protein (1.25 % of total) and 12.5 l of media (1.25 % of total) were
loaded. Proteins were detected with monoclonal anti-Notch3 antibody 3G6.
In transient transfection experiments in HEK293E cells, cellular expression and secretion
eﬃciency of the HaloTag fusion proteins were analyzed in comparison to the previously
used myc-His tag fusion protein. While Notch3-EGF1−5 expressed from the pFC15A vector
was detected in signiﬁcantly lower amounts in the medium fraction, production from the
pTT5 vector was comparable to myc-His tagged Notch3-EGF1−5 (Figure 2.2 B). Moreover,
a large fraction of the HaloTag fusion protein was secreted, although a residual signal was
observed in the cellular fraction, in contrast to the myc-His tagged protein. This result
19
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demonstrated that the combination of pTT5 vector and HaloTag yields protein levels in
the medium suﬃciently high for puriﬁcation purposes.
2.1.3 Optimization of the puriﬁcation procedure
We next analyzed the eﬃciency of Notch3-EGF1−5 Halo binding to the HaloLink resin
by varying several parameters: (1) incubation time (1 and 16 h); (2) amount of resin
used in the binding step; (3) addition of glycerol to reduce hydrophobic interactions and
(4) addition of -ME to test the inﬂuence of Notch3 structure on binding. Although the
addition of -ME breaks the structure of the protein and is therefore not suitable for pu-
riﬁcation, we tested its eﬀect to exclude possible structure related hindrances for correct
binding. Figure 2.3 A shows the ﬂowthroughs after HaloLink resin coupling representing
the amounts of unbound protein. Extending the coupling time had by far the strongest
eﬀect while increasing amounts of resin and the addition of glycerol had only little im-
pact. -ME treatment improved the binding suggesting an inﬂuence of Notch3 structure,
however, this caveat could be overcome by the increased coupling time.
We then performed a complete small-scale puriﬁcation procedure to estimate the ultimate
yield and quality of puriﬁed Notch3-EGF1−5 Halo. Gel electrophoresis and silver staining
of the material after TEV protease-mediated cleavage and its removal revealed the presence
of a single band of 25 kDa corresponding to the calculated size of Notch3-EGF1−5. No
degradation products were detected in signiﬁcant amounts (Figure 2.3 B).
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Figure 2.3: Optimization of Notch3-EGF1−5 puriﬁcation. A) Immunoblot with anti-Notch3
antibody 3G6 of ﬂowthroughs after the HaloLink binding step. HEK293E cells were transfected
with Notch3-EGF1−5 Halo and medium was collected after ﬁve days. Binding eﬃciency of diﬀerent
conditions was compared to conditioned medium before binding (input). Coupling time was varied
from two hours to 16 hours. Resin amount was doubled in one sample and inﬂuence on binding
of 5 % glycerol and 14 mM -ME was checked. B) Silver staining of a 15 % SDS-PAGE of eluted
Notch3-EGF1−5 shows no degraded low-size fragments.
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2.1.4 Large scale puriﬁcation
After optimizing the puriﬁcation protocol a large-scale puriﬁcation of wt Notch3-EGF1−5
was carried out. As established previously with the metal resin based puriﬁcation system,
medium was collected from four 500 cm2 ﬂasks of HEK293E cells transiently transfected
with Notch3-EGF1−5 Halo after ﬁve days. Each puriﬁcation step was controlled by silver
staining (Figure 2.4 A upper panel) and Western blotting (Figure 2.4 A lower panel).
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Figure 2.4: Large-scale puriﬁcation of Notch3-EGF1−5. A) Silver staining and Western
blotting of a representative puriﬁcation of wt Notch3-EGF1−5 with the HaloTag puriﬁcation sys-
tem. Media: Conditioned medium of transiently transfected HEK293E cells, Flow: Flow-through
after binding to HaloLink Resin, Eluate 1.1 and 1.2: fractions after TEV protease cleavage, Eluate
2: pooled eluate 1.1 and 1.2 after removal of TEV protease. Of note, the ratio of loaded sample
is, due to the diﬀerent volumes 18 times higher in the elution fractions compared to the media
and ﬂow fraction. Proteins on Western blot were analyzed with anti-Notch3 antibody 3G6. B)
Comparison of His-tag and HaloTag puriﬁcation concerning purity determined by silver staining.
Silver staining of the starting material revealed two prominent bands, one of ∼ 60 kDa
representing the HaloTag fusion protein (Figure 2.4 A upper panel). The comparison of
the starting material (Media) and the ﬂow through of the HaloLink resin (Flow) shows
a considerable reduction of the 60 kDa band indicating an eﬀective binding of the fu-
sion protein. Immunoblotting conﬁrmed that this band represents Notch3-EGF1−5 Halo.
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Stringent washing of the resin removed traces of remaining protein already in the ﬁrst
washing step (Wash 1). Addition of TEV protease led to the release of Notch3-EGF1−5
from the HaloLink (Eluate 1.1). Residual Notch3-EGF1−5 was recovered from the resin
by washing the beads again with buﬀer (Eluate 1.2). TEV protease (∼ 45 kDa) was ef-
ﬁciently removed from the pooled eluate fractions by binding to HisLink resin. In ﬁgure
2.4 B the increased purity of Notch3-EGF1−5 puriﬁed by the Halo technology in com-
parison to Notch3-EGF1−5 His is demonstrated. In addition, the yield of the puriﬁed
protein was improved by a factor of three resulting in 900 g of highly puriﬁed tag-free
wt Notch3-EGF1−5. In parallel, the mutant protein C183R was puriﬁed with a yield of
560 g.
2.1.5 Multimer formation of puriﬁed tag-free Notch3-EGF1−5
To analyze the multimerization behavior of tag-free Notch3 fragments puriﬁed via the Halo
technology, aliquots of the pure protein fractions of wt Notch3-EGF1−5 and the C183R
mutant were each labeled over night (o/n) with a 3-fold molar excess of Alexa488 (green)
or Alexa647 (red) succinimidylester and unbound dye was removed by desalting columns.
Proteins were aliquoted, frozen in liquid nitrogen and stored at −80◦C. For each experi-
ment a new aliquot was thawed and unspeciﬁc multimers pre-formed due to the freezing
procedure were removed by ultracentrifugation. A 1:1 mixture of green and red labeled
protein for each construct was incubated for ﬁve days at 37◦C on a rotary shaker. SIFT
analysis was performed at baseline, three days and ﬁve days (Figure 2.5). At baseline
none of the constructs showed any high-intensity signal indicating successful removal of
pre-formed multimers. During incubation the number of dual-color high intensity sig-
nals increased dramatically for the mutant but not for the wt protein. Quantiﬁcation of
seven independent experiments revealed that this eﬀect is robust and reproducible. This
demonstrated a diﬀerential multimerization behavior similar to that observed previously
for His-tagged Notch3-EGF1−5. We concluded that tag-free Notch3 fragments puriﬁed by
the HaloTag system are suitable for in vitro aggregation analysis.
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Figure 2.5: Spontaneous multimerization of tag-free mutant Notch3-EGF1−5. A) SIFT
analysis reveals dual-color high intensity signal of mutant Notch3-EGF after three and ﬁve days
indicating spontaneous de novo multimer formation of mutant protein, whereas wt remains in
the monomer form depicted as low intensity signal in the left lower corner of the histogram. B)
Quantiﬁcation of dual-color high-intensity SIFT signals from wt and mutant. Mean + standard
error of the mean (SEM) of seven independent experiments.
2.2 Aggregation analysis of cysteine-sparing Notch3 mutations
The overwhelming majority of Notch3 mutations associated with CADASIL lead to an
odd number of cysteine residues in one of the EGF-like repeats of the Notch3-ECD. How-
ever, over the last years several cysteine-sparing mutations have been reported to cause a
CADASIL-like phenotype and their relevance for the disease is controversially discussed
(see section 1.3.3). These ﬁndings are diﬃcult to reconcile with the currently favored
pathomechanism involving disulﬁde-mediated Notch3-ECD aggregation.
To gain insight into the possible pathogenicity of cysteine-sparing mutations we set out to
investigate their multimerization behavior in our SIFT assay. Since the Notch3 fragments
used in this assay comprises only EGF-like repeats 1− 5 we focused on mutations within
the ﬁrst 4 exons (Table 1.2). Four cysteine-sparing mutations within this region (R61W,
R75P, ∆A88-G91 and R213K) had been published74–79,82,83, a ﬁfth one (D80G) had been
identiﬁed in one of our own patients. As positive controls, we used the well-described
mutations R133C and C183R, as well as the C212Y mutation described in Bentley et al. 95 .
As negative controls besides wt we chose three single nucleotide polymorphisms (SNPs)
from the exome sequencing project (ESP) (R113Q, H170R and G179V) with an allele
frequency of at least 0.1% which had so far not been associated with CADASIL (Table
1.2). Although the mutation H170R had been described as disease causing by Ampuero
et al. 87 , there was evidence that it can be considered as a rare polymorphism, since
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no clinical details of the patient were presented and it emerged as polymorphism in our
database research. Thus, this variant was classiﬁed as polymorphism.
2.2.1 Cysteine-sparing mutants are eﬃciently expressed and secreted
All Notch3 mutant constructs were generated by mutagenesis from the pTT5 Notch3-
EGF1−5 Halo plasmid and veriﬁed by sequencing. Their expression and secretion eﬃ-
ciencies after transient transfection into HEK293E cells were analyzed after three days by
Western blotting. Equal protein amounts were loaded and medium volume was adjusted
to the corresponding lysate. Detection with an anti-Notch3 antibody revealed cellular
expression levels as well as secretion eﬃciencies in the medium comparable to wt Notch3
demonstrating the suitability of the mutant fragments for large-scale puriﬁcation (Figure
2.6).
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Figure 2.6: Expression analysis of diﬀerent Notch3 variants. HEK293E cells were tran-
siently transfected with Notch3-EGF1−5 constructs bearing diﬀerent amino acid changes or the
wt form. Medium and cells were harvested three days after transfection. Protein concentration
of cell lysates was determined and adjusted. Volume of conditioned medium was adjusted to the
corresponding cell lysate. Amount of expressed Notch3-EGF1−5 in conditioned medium (M) and
cell lysate (L) under reducing conditions was determined by immunoblotting. Transfected wt and
C183R samples served as control on both blots. Proteins were detected using anti-Notch3 antibody
3G6.
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Notch3-EGF1−5 fragments carrying various polymorphisms or mutations were puriﬁed in
large scale using the HaloTag technology. Purity and yield of most variants was comparable
to wt Notch3-EGF1−5, except for the R133C and C183R mutations having lower yields
(Figure 2.7).
WT R113Q H170R G179V R133C C183R C212Y R61W R75P D80G 88-91R213K
25
37
50
75
kDa
Yield [µg] 900 864 900 714 344 560 444 1160 700 766 694 720
Figure 2.7: Purity and yield of all puriﬁed Notch3-EGF1−5 mutation variants. Silver
staining of ﬁnal eluates from puriﬁed mutant Notch3-EGF1−5 constructs including wt. All puri-
ﬁed mutant proteins showed high purity comparable to wt. Final protein yield was determined
by protein concentration measurements. Amount of protein for most mutants obtained in one
puriﬁcation was comparable to wt, only the R133C and C183R mutation showed reduced yields.
2.2.2 Cysteine-sparing mutants show diﬀerential aggregation behavior
Puriﬁed Notch3-EGF1−5 fragments containing classical CADASIL mutants, cysteine-
sparing mutants and polymorphisms were ﬂuorescently labeled and their multimerization
potential was analyzed by SIFT at baseline, three and ﬁve days. Figures 2.8 and 2.9 show
the raw data of representative experiments and Figure 2.10 shows the quantiﬁcation of six
independent experiments. At baseline, high-intensity signals were low for all variants ex-
amined, demonstrating the absence of preformed aggregates. In the polymorphism group
none of the variants showed a stronger aggregation tendency than the wt protein suggesting
no aggregation potential. In contrast, all three cysteine mutants displayed a signiﬁcant
increase in high-intensity signals after three and ﬁve days of incubation demonstrating
their well-established aggregation potential (Figure 2.8).
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Figure 2.8: Aggregation assay with polymorphisms and canonical cysteine-aﬀecting
mutations of Notch3-EGF1−5. Representative 2D histogram plots show multimerization for
A) wt and polymorphisms and B) cysteine-aﬀecting mutants at baseline and after incubation for
three and ﬁve days at 37◦C. Polymorphisms show no or only low aggregation potential comparable
to wt. In contrast, the cysteine mutants exhibit an increased multimer signal after incubation.
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For the various cysteine-sparing variants diﬀering results were obtained. R213K, the only
reported cysteine-sparing mutation with a conservative exchange of amino acids (basic →
basic) showed the lowest multimerization tendency suggesting that it in fact represents a
polymorphism. For R61W, an increase was observed after three and ﬁve days but total
signal levels were not higher than with wt protein or the H170R polymorphism (Figure 2.9
). However, the three variants R75P, D80G and ∆A88-G91 showed a signiﬁcant increase
which was as strong as with the classical mutants (Figure 2.10).
This data indicate that indeed some cysteine-sparing mutations in Notch3-EGF1−5 favor
the aggregation process of the protein in vitro. The potential consequences of our ﬁndings
are discussed in section 3.1.
baseline
(0 d)
3 d, 37°C
5 d, 37°C
250
125
0
0 125 250
250
125
0
0 125 250
250
125
0
0 125 250250
250
0 125 250
250
125
0
0 125 250
250
125
0
0 125 250
250
125
0
0 125 250250
250
0 125 250
250
125
0
0 125 250
250
125
0
0 125 250
250
125
0
0 125 250
R61W R75P D80G 88-91 R213K
Figure 2.9: Aggregation assay with cysteine-sparing Notch3-EGF1−5. Representative 2D
histogram plots of cysteine-sparing Notch3-EGF1−5 mutations show mixed results. While R75P,
D80G and ∆88-91 show after incubation multimer signals similar to classical cysteine mutations,
the aggregation potential of R61W and R213K is as low as in wt and polymorphisms.
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Figure 2.10: Analysis of spontaneous in vitro multimerization. The quantiﬁcation of
dual-color high-intensity signals from SIFT analysis shows the mean + SEM of six independent
experiments. After incubation, the cysteine-aﬀecting mutants show a higher multimer signal com-
pared to wt and therefore serve as positive control group. This increase is mostly absent in the
polymorphisms serving as negative control group. Results from the cysteine-sparing group are
variable with three mutations having a signiﬁcant increase in multimer signal after incubation
but two with low or completely without multimer signal. Group statistics compared with wt at
the same time point; ∗ p<0.05 (post hoc Wilcoxon signed-rank sum test with false discovery rate
correction).
2.3 Identiﬁcation of Notch3 aggregation inhibitors
2.3.1 Synthetic small-molecule compounds
To date, there is no cure for CADASIL. Since the aggregation of Notch3 plays a key role
in the pathogenesis of the disease, inhibiting or modulating this process would serve as a
basis for a pharmacological therapy. Being able to monitor the aggregation of CADASIL-
mutated Notch3 in vitro with our SIFT assay provides the opportunity to test small-
molecule compounds for antiaggregatory activity. The potential of anti-aggregatory treat-
ment is currently intensely investigated in several neurodegenerative diseases including
prion disease and PD.96–98 The substance class of diphenylpyrazole (DPP)-based com-
pounds (Figure 2.11) has been shown to be eﬀective in preventing aggregation of PrP and
-syn98 We therefore selected 15 compounds of this class to test their eﬃciencies in our
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Notch3 aggregation assay. Puriﬁed Notch3-EGF1−5 fragment containing the archetypal
C183R mutation (see section 2.1) was used throughout this study.
N NH
Figure 2.11: Lead structure di-phenyl-pyrazole (DPP).
All compounds were dissolved in DMSO and used at a ﬁnal concentration of 10 M in
1% DMSO as described in previous studies98. They were added to ﬂuorescently labeled
Notch3-EGF1−5 C183R at baseline and the formation of multimers was measured at day
three and ﬁve. DMSO alone had no signiﬁcant eﬀect on the aggregation behavior of the
C183R mutant (Figure 2.12). Figure 2.13 A shows representative data of an experiment
with anle138b (no inhibition), sery118 (weak inhibition) and anle138c (strong inhibition).
Quantiﬁcation of the data at day ﬁve from all compounds conﬁrmed the wide range of
inhibition eﬃciencies. While three compounds (anle138b, anle 253b and anle 137b) had no
eﬀect, six compounds (sery118, sery139, sery144, sery320a, sery95 and sery159a) resulted
in a moderate but signiﬁcant signal decrease and six compounds (anle138c, anle136c,
sery106, anle 137c, sery166a and sery105) showed a reduction of more than 88 % (Figure
2.13 B).
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Figure 2.12: Inﬂuence of DMSO on aggregation behavior of Notch3-EGF1−5 C183R.
Quantiﬁcation of SIFT signal at baseline and at day three and ﬁve after incubation at 37◦C of mu-
tant Notch3-EGF1−5 shows normal aggregation behavior with addition of 1 % DMSO comparable
to negative control. No signiﬁcant diﬀerence could be detected. Mean and SEM of six independent
experiments. Group statistics compared at the same time points (Mann -Whitney test).
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Figure 2.13: Aggregation inhibition using synthetic small molecule compounds. A)
Representative 2D histogram plots show either no (anle138b), weak (sery118) or strong (anle138c)
inhibition of multimer formation after addition of 10 M compound to Notch3-EGF1−5 C183R
at baseline and incubation for ﬁve days at 37◦C compared to DMSO control. B) Quantiﬁcation
of dual-color high-intensity SIFT signals at day ﬁve for de novo inhibition of mutant Notch3
aggregation using diﬀerent DPP derivatives at a ﬁnal concentration of 10 M in 1 % DMSO. Mean
+ SEM of four independent experiments; group statistics compared with DMSO control at the
same time point; ∗ p<0.05; ∗∗ p<0.01; ∗∗∗ p<0.001 (Mann-Whitney test).
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Analysis of the compound structures revealed that hydroxyl groups (OH groups) might
be required for eﬃcient inhibition of Notch3 aggregation, since only substances containing
at least one OH group showed inhibitory activity (Table 2.1). Even more notable were
the diﬀerential eﬀects with pairs of highly related compounds. While anle138c (two OH
groups) and anle137c (three OH groups) displayed strong anti-aggregatory activity, anle
138b and anle 137b (both without OH group) were only weakly eﬀective. We, there-
fore, concluded that OH groups were essential for aggregation inhibition. However, other
structural features of the compound appear to be crucial for inhibitory activity as well.
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Table 2.1: Structure-activity relationship for various DPP-derivatives.
Comp. Structure % inh. Comp. Structure % inh.
sery105 94 sery320a 68
sery166a 91 sery144 58
anle137c 91 sery139 55
sery106 91 sery118 44
anle136c 90 anle137b 27
anle138c 88 anle253b ≤ 10
sery159a 76 anle138b ≤ 10
sery95 76
All compounds were tested at a ﬁnal concentration of 10 M, a concentration that reﬂects
best physiological conditions. Since lower dosages with a high inhibition potency would
be favorable for further drug developments, we next analyzed a possible dose-response
relationship for two of the most potent inhibitors, anle138c and sery166a. Their eﬀect on
the C183R mutant aggregation was analyzed at 0.1, 0.3, 1, 3 and 10 M concentration.
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Analysis of this data revealed that the high-intensity SIFT signal decreases with increasing
compound concentration. Highest signals could be found in the DMSO control, whereas
no multimeric signal could be observed with a compound concentration of 10 M. At 1
M both compounds showed signiﬁcant inhibition of more than 50 %. For sery166a this
was already the case at 0.3 M (Figure 2.14). No diﬀerence in baseline signal could be
observed for both compounds. These data conﬁrm that both compounds have a high
inhibition eﬃcacy, thus inhibiting Notch3 aggregation already at low concentrations.
S
IF
T
 s
ig
n
a
l 
(b
in
s
)
0
50
100
150
200
250
300
350
400
baseline
5 d
DMSO 10 µM3 µM1 µM0.3 µM0.1 µM
0
50
100
150
200
250
300
350
400
S
IF
T
 s
ig
n
a
l 
(b
in
s
)
DMSO 10 µM3 µM1 µM0.3 µM0.1 µM
A
B C
250
125
0
0 125 250
250
0 125 250 0 125 250
*
250
125
0
0 125 2500 125 250 0 125 250
5 d, 37°C
DMSO 10 µM3 µM1 µM0.3 µM0.1 µM
**
*
***
*
*
baseline
5 d
anle138c sery166a
Figure 2.14: Dose dependency of anle138c and sery166a on Notch3-EGF1−5 aggre-
gation. A) SIFT-signal revealed decrease in high-intensity signals with increasing compound
concentration at day ﬁve. B+C) Dose-dependency curves of anle138c (B) and sery166a (C) at
baseline and day ﬁve. Concentrations decline from 10 M to 0.1 M in 1 % DMSO. Mean + SEM
of four independent experiments; group statistics compared with DMSO control at the same time
point; ∗ p<0.05; ∗∗ p<0.01 (Mann-Whitney test).
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2.3.2 Natural polyphenolic compounds
In our analysis of diﬀerent synthetic small molecule compounds we could deﬁne the pres-
ence of one or more OH groups as a key feature for eﬀective inhibition of Notch3 aggrega-
tion (see section 2.3.1). An important class of compounds characterized by the presence
of multiple OH groups on aromatic rings are the natural polyphenolic compounds. They
are abundant in a wide range of fruits, herbs, vegetables and beverages (Table 2.2) and
have been well studied in a variety of clinical conditions including neurodegenerative dis-
eases99,100. Most notably, they have been demonstrated to inﬂuence the aggregation of
-syn in vitro, a process crucial for the development of PD.96,97 Since their bioavailability
and physiological tolerance have been studied extensively, we decided to test a variety of
them for their ability to inhibit Notch3 aggregation.
Table 2.2: List of natural polyphenolic compounds used in this work. All natural polyphe-
nolic compounds are listed together with their chemical description and source. BTE: black tea
extract, EGCG: (-)-epigallocatechin gallate
Name Class Source
Apigenin ﬂavone chamomile, celery, parsley
Baicalein ﬂavone roots of Scutellaria baicalensis
BTE ≥ 80 % theaﬂavins black tea
Catechin ﬂavanol apples, barley, black currant, cocoa, peaches
Chrysin ﬂavone chamomile, honeycomb, passion ﬂower
Curcumin diarylheptanoid tumeric
EGCG ﬂavanol black-eyed peas, cocoa, grapes, lentils, tea, wine
Fisetin ﬂavanol apples, grapes, onions, strawberries, tea, wine
Genistein isoﬂavone red clover, soybeans
Gingkolide B terpenic lactones gingko leaves
Morin ﬂavonol Osage orange, old fustic, leaves of common guava
Myricetin ﬂavonol black currant, grapes, walnuts
Propylgallate phenylpropanoid artiﬁcial food additive
Quercetin ﬂavanol apples, beans, broccoli, wine
Resveratrol stilbenoid red grape skins, roots of Japanese knotweed, red wine
Rosmarinic acid phenolic acid basil, lemon balm, marjoram, rosemary, sage
Tannic acid phenolic acid woods
We selected 16 natural polyphenols and black tea extract (BTE), which contains > 80 %
polyphenolic compounds, to investigate their eﬀect on Notch3 aggregation (Figure 2.15).
Of interest, nine of them belong to the group of ﬂavonoids (Figure 2.15 boxed compounds),
which includes ﬂavones, isoﬂavones and ﬂavanols (Table 2.2) and show a similar structure
as the most potent synthetic inhibitors anle138c and sery166a evaluated in section 2.3.1.
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Figure 2.15: Chemical structure of natural polyphenols used in this work. Compounds
within the box represent ﬂavonoids.
The remaining compounds belong to molecule classes with unrelated structures, but all
contain at least two OH groups. (Fig. 2.15). Similar to the analysis of synthetic compounds
natural polyphenols were tested in the SIFT assay at a ﬁnal concentration of 10 M on
Notch3-EGF1−5 R183C fragments for three and ﬁve days. Data from a representative
experiment with apigenin (no inhibition), BTE and baicalein (both strong inhibition) are
shown in Figure 2.16 A. Quantitative analysis at day ﬁve of four experiments performed
with all compounds revealed inhibition eﬃciencies between 50 and 85 % with almost half
of the compounds (morin, resveratrol, tannic acid, catechin, quercetin, rosmarinic acid,
baicalein and BTE) showing a signiﬁcant reduction (Figure 2.16 B). However, the overall
inhibitory eﬀect was weaker compared to the synthetic small-molecule compounds. The
weakest signiﬁcant change could be observed with the ﬂavanole morin (50 % inhibition),
whereas the strongest eﬀect could be obtained with BTE (75 % inhibition), which consists
about 80 % of theaﬂavins. This result is comparable to the inhibition eﬃciency of the
middle group of synthetic compounds that show a signiﬁcant aggregation inhibition up to
25 %. However, we could not identify more potent inhibitors within this set of natural
polyphenols that could reduce the aggregation further.
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Figure 2.16: Aggregation inhibition using natural polyphenolic compounds. A) Repre-
sentative 2D histogram plots show either no (apigenin) or strong (baicalein and BTE) reduction
of multimer formation after addition of 10 M compound to mutant Notch3-EGF1−5 at baseline
incubation for ﬁve days at 37◦C compared to DMSO control. B) Quantiﬁcation of dual-color high-
intensity SIFT signals at day ﬁve for de novo inhibition of Notch3-EGF1−5 C183R aggregation
using natural polyphenolic compounds at a ﬁnal concentration of 10 M in 1 % DMSO. Mean +
SEM of four independent experiments; group statistics compared with DMSO control at the same
time point; ∗ p<0.05; ∗∗ p<0.01 (Mann-Whitney test).
These data not only demonstrate that SIFT-analysis is an ideal method to identify potent
inhibitors of Notch3 aggregation in vitro in diﬀerent compounds classes, but also suggested
that structural analysis of aggregate-compound interaction would need further investiga-
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tion. Still, we have revealed diﬀerent compounds, synthetic as well as natural, that could
serve as pharmacological basis for an eﬃcient drug development for CADASIL.
2.3.3 Dissolution of preformed aggregates
The formation of Notch3 aggregates and GOM deposits represents an early event in
CADASIL pathogenesis.68 Thus, the dissolution of preformed aggregates would be a highly
desirable feature of clinically interesting inhibitors. We addressed this question by test-
ing the eﬃcacy of the most potent of our identiﬁed aggregation inhibitors on pre-formed
Notch3-EGF1−5 C183R multimers. Our previous studies have shown aggregate dissolution
is principally possible using a combination of 1 % SDS and 1 % -ME71 and we used this
condition as positive control. We ﬁrst performed a pilot experiment with two of the most
potent inhibitors anle183c and baicalein to test the dissolution kinetics. Notch3 multimers
were pre-formed over ﬁve days and after addition of the compounds at a ﬁnal concentra-
tion of 10 M, SIFT signals were measured at baseline, two and four hours. As depicted
in ﬁgure 2.17, neither baicalein nor anle183c exhibited signiﬁcant eﬀects within the used
time periods, while SDS and -ME treatment led to a complete loss of the multimer signal
immediately after addition.
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Figure 2.17: Dissolution analysis within four hours. Pre-formed Notch3 aggregates were
incubated with 10 M baicalein, anle138c and the combination of 1 % SDS and 1 %-ME as
control, respectively, and analyzed over a time period of four hours. The addition of SDS and
-ME resulted immediately in a loss of the multimer signal, whereas the addition of baicalein or
anle138c did not show any eﬀect.
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Next, we prolonged treatment time to 24 hours to account for possible slow dissolution
kinetics and examined seven synthetic and four natural compounds. Figure 2.18 shows the
raw data of a representative experiment and Figure 2.19 the quantiﬁcation of three inde-
pendent experiments. Similar to the inhibition experiments, synthetic compounds showed
a much stronger activity compared to natural polyphenols with anle137c and anle138c as
most potent molecules with dissolution rates about 90 %. In contrast, their close deriva-
tives anle137b and anle138b showed no activity at all indicating that inhibition of aggregate
formation and aggregate dissolution are mediated by the same chemical groups. As most
potent natural polyphenols baicalein and rosmarinic acid turned out with dissolution rates
of 50-60 %. Interestingly, BTE did not show any dissolution eﬀect despite representing
the most potent aggregation inhibitor suggesting a mechanism of action diﬀerent from the
other compounds.
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Figure 2.18: Dissolution of pre-formed Notch3 multimers. Pre-formed Notch3 aggregates
were incubated with 10 M of diﬀerent compounds for 24 hours and subsequently analyzed. Com-
pounds could be divided into two groups: One that had no or little dissolution eﬀect, and the other
that showed the ability to dissolve pre-formed aggregates almost completely.
Taken together, these data demonstrate that Notch3 aggregation in vitro can be inhibited
eﬃciently by diﬀerent small-molecule compounds. The much slower kinetics compared to
artiﬁcial aggregate dissolution indicates that the process is speciﬁc. Substances containing
OH group might be promising candidates for high-eﬃciency inhibitors. Thus, selected
compounds are worth to be examined further.
38
2.4. Notch3 aggregation analysis in cultured MEF
0
20
40
60
80
100
120
140
160
180
%
 o
f 
b
a
s
e
lin
e
 (
5
 d
)
DM
SO
an
le1
37
b
BT
E
an
le1
38
b
EG
CG
Ro
sm
ari
nic
ac
id Ba
ica
lei
n
se
ry9
5
se
ry1
66
a
se
ry1
06
an
le1
37
c
an
le1
38
c
Figure 2.19: Analysis of pre-formed Notch3 multimer dissolution. Quantiﬁcation of
the relative amount of high-intensity SIFT-signals after dissolution compared to the pre-formed
multimers. Mutant Notch3 was pre-formed for ﬁve days at 37◦C, inhibitors from the synthetic small
molecule group as well as from the natural polyphenols were added with a ﬁnal concentration of
10 M and the mix was further incubated for one day at 37◦C. Mean + SEM of three independent
experiments.
2.4 Notch3 aggregation analysis in cultured MEFs
Having identiﬁed compounds with anti-aggregatory Notch3 activity in our SIFT assay, we
sought to develop a more physiological system for validating the most promising candi-
date inhibitors. In CADASIL patients GOM deposition occurs in the extracellular space
within vessel walls. Thus, Notch3 deposits are likely to occur within the ECM network
and proteomic studies strongly suggest that ECM components are part of the GOM.72
Fibroblasts, a major source for the production of ECM proteins, can be cultivated ex vivo
and are amenable for manipulations such as DNA transfection. We therefore used MEFs
to investigate whether the Notch3 aggregation process can be recapitulated under tissue
culture conditions.
2.4.1 Transfected MEFs show mutant Notch3 enrichment in the extracellular
matrix
All following experiments were performed with ﬁve independent MEF cell lines isolated
from 14.5-dpc (days post coitus) embryos of wt mice and immortalized through serial
passaging by Scharrer 101 .
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When seeded on a plastic dish and grown to conﬂuence, these ﬁbroblast lines produce
an extensive ECM within two to ﬁve days. For the analysis of ECM proteins by Western
blotting the culture medium was removed and the cells were lysed with a buﬀer containing
0.1% Triton and 20 mM NH3. This resulted in a mild cell lysis due to a combination of
low detergent concentrations and osmotic swelling (Figure 2.20). After collection of cell
lysates and repeated washing steps the ECM was recovered in a Tris buﬀer containing
1 % SDS and samples were homogenized by pasing through a 25G syringe. Using this
extraction method a separation of the cellular and ECM protein fractions was achieved.
ECM
removal
Figure 2.20: Scheme of matrix separation. Cultured MEFs build up a stable ECM. After
growing them for two or ﬁve days, the cells were treated with a mixture of 0.1 % Triton as a mild
detergent in combination with 20 mM NH3, that leads to an unbalanced osmotic pressure within
the cells leading to cell lysis without aﬀecting the ECM. After several washing steps the ECM was
resuspended in buﬀer containing 1 % SDS.
To analyze the behavior of Notch3 in this system, transfection of ﬁbroblasts with wt
and C183R mutant Notch3-EGF1−5 fragments containing a C-terminal myc-His tag was
performed. As we could already show in HEK293E cells, these truncated ECD constructs
are eﬃciently secreted (Figure 2.2). Cells were transfected after reaching∼ 90 % conﬂuence
and harvested ﬁve days later. Immunodetection of Notch3 fragments was achieved with
an anti-myc antibody. As control for the purity of our preparations and for equal gel
loading we used antibodies against ﬁbronectin, platelet-derived growth factor receptor beta
(PDGFR) and tubulin. Fibronectin is secreted from ﬁbroblasts and incorporated into
the ECM, PDGFR is a transmembrane receptor and was used to monitor the absence
of plasma membrane proteins in the ECM fraction and tubulin is a cytosolic protein
found exclusively in the cellular fraction. Immunoblotting for these proteins revealed
a high extent of separation between medium, cellular and ECM fraction (Figure 2.21).
Fibronectin was detected only in the medium and the ECM indicating that our cell lysis
conditions did not aﬀect the matrix. Furthermore, cell lysis was complete, as a tubulin
signal was visible only in the lysate fraction. The main fraction of cell membranes could
also be removed as evident from the very low PDGFR signal present in the ECM fraction.
Labeling with the anti-myc antibody revealed comparable secretion of wt and C183R
Notch3 into the medium. In the cell lysate fractions only little amounts of Notch3, both
wt and C183R mutant, could be observed, whereas the ECM fraction revealed a strong
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enrichment of mutant but not wt Notch3. In the cellular and ECM fractions several bands
of higher molecular weight were observed (Figure 2.21 asterisks), but appeared also in the
control lanes and thus represent unspeciﬁc signals. The signal at about 60 kDa possibly
represents Notch3 dimers.
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Figure 2.21: Mutated Notch3 EGF1−5 but not wt accumulates in the ECM fraction.
MEFs were transfected with either Notch3 EGF1−5 myc-His C183R, wt or empty vector (mock).
Conditioned media, cell lysates and ECM fraction were collected after ﬁve days and analyzed
by Western blotting under reducing conditions. Purity and equal loading for each fraction was
controlled using antibodies against ﬁbronectin for the conditioned media and the ECM fraction
and against tubulin for the cell lysates. Immunoblotting with an antibody against PDGFR, a
transmembrane protein, served as control for identifying traces of cell membrane remaining in
the ECM fraction. Whereas both, wt and C183R Notch3 EGF1−5, show equal secretion into
conditioned media, only the mutant accumulates in the ECM fraction as detected by the anti-myc
antibody. ∗ indicate unspeciﬁc bands.
To further investigate the Notch3 accumulation process, we harvested transfected MEFs
at two diﬀerent time points, two and ﬁve days after transfection. Figure 2.22 shows
that already after two days mutant Notch3-EGF1−5 could be detected in the matrix in a
considerable amount. After ﬁve days, the signal of the monomeric form did not increase
signiﬁcantly, but bands of higher molecular weight appeared likely representing dimers,
trimers and higher order oligomers. In contrast, no signiﬁcant amounts of wt Notch3 were
detected in the ECM fraction.
To verify the enrichment of mutant Notch3 in the ECM, we performed immunoﬂuorescent
microscopy. We treated the MEF culture in the same way as for matrix harvesting, but
ﬁxed the cells ﬁve days after transfection with 4 % PFA and stained with antibodies against
ﬁbronectin and myc tag. We did not permeabilize the cells with any detergent, thus, only
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Figure 2.22: Mutated Notch3 EGF1−5 shows high molecular bands in the ECM frac-
tion. ECM fractions of MEFs were harvested 2 days and 5 days after transfection, respectively.
Immunoblotting with the anti-myc antibody under reducing conditions revealed after 2 days a
monomeric Notch3-EGF1−5 of mutant C183R. After 5 days an additional band of ∼ 58 kDa, likely
a dimer, and several bands of higher molecular weight (#), possibly higher-oder oligomers, ap-
peared. None of those bands could be detected in signiﬁcant amounts with the wt construct. ∗
indicate unspeciﬁc bands.
extracellular proteins were detected. Staining for ﬁbronectin revealed an extensive ﬁbrillar
network demonstrating that an ECM had been formed by the ﬁbroblasts. Similar to the
immunoblotting results Notch3 deposition in the ECM could only be detected with C183R
but not wt protein (Figure 2.23).
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Figure 2.23: Deposits of mutated Notch3 EGF1−5 but not wt are localized in the ECM
of MEFs. Transfected MEFs were ﬁxed with 4 % PFA remaining non-permeabilized. Cells were
stained with antibodies against ﬁbronectin and myc, the latter for detecting myc-tagged Notch3
EGF1−5, and analyzed by immunoﬂuorescence.
Higher resolution images of the matrix from mutant expressing cells showed Notch3 stain-
ing in a dot-like structure along extracellular ﬁbers, partly also stained for ﬁbronectin
(Figure 2.24). This suggested that mutant Notch3 accumulates locally within the ECM
of ﬁbroblasts and provided strong evidence that the aggregation of CADASIL-mutant
Notch3-EGF1−5 fragments can be recapitulated in cultured cells.
10 µm
Fibronectin
C183R
Notch3 DAPI + Merge
Figure 2.24: Notch3 EGF1−5 C183R is enriched in a dot-like structure in the ECM
and shows an intense accumulation pattern. Non-permeabilized MEFs transfected with
Notch3 EGF1−5 C183R were stained with antibodies against ﬁbronectin and myc and analyzed by
immunoﬂuorescence.
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2.4.2 Preselected compounds show diﬀerent eﬀects on extracellular Notch3
In section 2.3 we identiﬁed several potent small molecule compounds that could eﬀectively
inhibit the formation and promote the dissolution of Notch3 aggregates in vitro. However,
the GOM accumulation in vivo likely involves factors other than Notch3 and potential ag-
gregation inhibitors have to be eﬃcient also in such more complex systems. We, therefore,
used pre-selected inhibitors in our established cell culture assay to test their eﬀect in a
more physiological setting.
We performed the assay as described in section 2.4.1. Since we could demonstrate that
already two days after transfection a detectable amount of mutated Notch3 is enriched in
the ECM fraction (Figure 2.22), we started the compound treatment at this time point.
We added anle138b, anle138c and baicalein at a ﬁnal concentration of 10 M to the
medium and incubated the cells for three more days. Control cells were treated with the
same volume of 1 % DMSO.
Immunoblot analysis of conditioned media with the anti-ﬁbronectin antibody showed that
treatment with the compounds did not impair protein secretion (the weaker signal in the
control sample was due to reduced protein loading) (Figure 2.25).
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Figure 2.25: Notch3 EGF1−5 myc-His ECM accumulation is reduced by compound
treatment. MEFs were transfected with mutant Notch3 EGF1−5-myc C183R. Two days after
transfection, preselected compounds anle138b, anle138c and baicalein were added at a ﬁnal con-
centration of 10 M and incubated for three more days. DMSO served as control. ECM was
harvested and analyzed together with conditioned media by Western blotting. Proteins were de-
tected with anti-ﬁbronectin and anti-myc antibodies.
Staining for the Notch3 mutant revealed a strong reduction upon treatment with baicalein
and anle138c, both very eﬀective compounds, in the in vitro assay. For anle138b, which
had shown no eﬀect in vitro, a much less pronounced reduction was observed. Moreover,
bands of higher molecular weight likely representing Notch3 C183R oligomers were also
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reduced in a manner comparable to monomers further indicating an inhibition of Notch3
oligomerization. These data indicate that the cellular assay largely recapitulates the eﬀects
of anti-aggregatory compounds from the SIFT assay.
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The accumulation and aggregation of the Notch3-ECD is a hallmark of the monogenic
SVD CADASIL and considered the starting point of a series of pathological events even-
tually resulting in the malfunction of the cerebral microvasculature.63 The aggregation
process, which is typically initated by NOTCH3 mutations aﬀecting the number of cys-
teine residues, has recently been recapitulated in an in vitro assay by using the single
molecule detection technique SIFT. In this thesis the assay was further optimized, applied
to the investigation of the pathogenic potential of rare cysteine-sparing mutations and
used to screen for small-molecule compounds with anti-aggregatory properties.
To improve yield and purity of the Notch3 fragments required for the SIFT assay, the
HaloTag puriﬁcation system was used allowing the more eﬃcient removal of contaminat-
ing proteins during the puriﬁcation procedure and the protease-mediated elution of Notch3
proteins from the aﬃnity matrix. This yielded in highly pure protein without aﬃnity tag
and in two-fold higher amounts than with the previously used His-tag-mediated puriﬁca-
tion. Furthermore, the usage of EDTA in the elution step was no longer required and the
puriﬁed protein could be obtained in the ﬁnal aggregation buﬀer. Its analysis in the SIFT
assay revealed an aggregation behavior of wt and mutant variants comparable to previous
experiments.
3.1 Cysteine-sparing Notch3 variants can be pathogenic
For decades the prevailing dogma in the CADASIL ﬁeld stated that only a change in the
number of cysteine residues and thus in the organization of disulﬁde bridges can initi-
ate missfolding and trigger aggregation of the Notch3-ECD. However, in the last years
the question whether cysteine-sparing Notch3 variants represent only polymorphisms or
pathogenic mutations has been heavily debated.73,81,102 At least in some cases including
one reported by our group85 strong evidence for a clinical relevance emerged. We there-
fore decided to study the pathogenic potential of ﬁve of these mutations in our in vitro
aggregation assay in comparison to wt Notch3, three well-characterized cysteine mutants
and three non-pathogenic polymorphisms. The latter are deﬁned by their high prevalence
in the population (0.1 to 0.3 % allele frequency in the ESP). Whereas their multimeriza-
tion behavior was comparable to wt protein, the three selected cysteine mutants showed
a signiﬁcant increase of multimer signal at day three and ﬁve. The outcome of the ﬁve
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selected cysteine-sparing mutants was variable , with R75P, D80G and ∆A88-G91 showing
multimerization comparable to the cysteine mutants, and R61W and R213K revealing no
signiﬁcant signal. These inconsistent results led us to reevaluate the reported clinical data
of the mutation carriers (Table 3.1).
Table 3.1: Evaluation of cysteine-sparing mutants.
Mutation Biochemical Accuracy of SIFT
properties clinical data aggregation
R61W basic → aromatic − −
R75P basic → structural + +
D80G acidic → aliphatic + +
∆A88-G91 deletion + +
R213K basic → basic − −
The data available for the three variants showing an eﬀect in our assay further support
their classiﬁcation as pathogenic mutations. R75P is the best characterized cysteine-
sparing mutation to date with data available from several Asian families.77–79,83,84 MRI
ﬁndings of patients were typical for CADASIL and the presence of GOM deposits could
be demonstrated providing convincing evidence for the diagnosis. Furthermore, the re-
placement of a basic arginine residue by a bulky proline, a known structural disruptor of
-helices and -sheets, likely leads to a conformational change of the aﬀected EGF-like
repeat increasing the aggregation potential.
The D80G mutation was found in four patients, but neither in healthy members of a
aﬀected German family nor in control genomes from the ESP.85 The mutation carriers
showed an archetypical CADASIL phenotype in absence of vascular risk factors. Although
the presence of GOM could be shown in only one subject, all aﬀected family members
showed T2-hyperintense lesions in the temporal pole, which is the most prominent MRI
ﬁnding in CADASIL patients. The replacement of an acidic aspartate by a small aliphatic
glycine is also likely to inﬂuence the protein conformation.
The ∆A88-G91 deletion was identiﬁed in one Italian family.76 Although the patient num-
ber (2) is small, the pathogenicity of the mutation can be considered as well documented
on the basis of clinical and histological data. Although no cysteine is aﬀected, the deletion
of four amino acids changes the highly conserved distance between two cysteine residues
likely disrupting the protein structure in a signiﬁcant way.
In contrast, the R61W and R213K mutations did not exhibit signiﬁcant multimer for-
mation raising doubts about their clinical relevance. This is supported by the incomplete
description of their clinical phenotype. Although the two siblings with the R61W mutation
suﬀered from migraine and stroke-like episodes, their white matter lesions as determined
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by MRI were atypical. Furthermore, they had no family history for neurological deﬁcits.82
The presence of GOM deposits was reported, but only from the patient’s brother carrying
the same mutation. Thus, the clinical evidence for CADASIL in this case was not entirely
convincing. Moreover, recent data from the ESP revealed an allele frequency for the R61W
variant of 0.05 % in Americans of European origin, (Table 1.2), a number far higher than
the estimated CADASIL prevalence of 2-4/100,000.103 Although the replacement of a basic
arginine by an aromatic phenylalanine residue may also cause an interruption of secondary
protein structure, we tend to the conclusion that R61W is rather a polymorphism than
a disease-causing mutation. However, additional investigations including detailed struc-
tural analysis and comprehensive examination of more patients carrying this mutation are
required to make a deﬁnite statement.
The R213K mutation was found in a single autopsy case with questionable genetic, clinical
and histological data.74,75 Only mild migraine, moderate dementia and gait disturbance
were reported as neurological and neurophysiological symptoms. The authors even con-
sidered the possibility of a vascular disease diﬀerent from CADASIL74 or a rare polymor-
phism.75 Although we could not ﬁnd this variant in the ESP, we still consider it as rare
polymorphism, an assumption supported by the conservative nature of the amino acid
exchange, with the substitution of one basic amino acid by another basic one.
In summary, our in vitro aggregation data provide further evidence for the pathogenicity
of some cysteine-sparing mutations raising two possibilities as underlying mechanisms.
First, such an amino acid exchange may lead to a conformational change which in turn
results in the disruption of an existing disulﬁde bond. As a consequence two unpaired
cysteines would be generated triggering a sulfhydryl group-mediated multimerization sim-
ilar to cysteine mutants. Second, the cysteine-sparing amino acid exchange may lead to
misfolding via a cysteine-independent mechanism such as exposing hydrophobic parts and
triggering the formation of -sheet-rich oligomeric structures, a common cause of protein
aggregation. Although contradicting the current view of disulﬁde-mediated Notch3 ag-
gregation, this possibility has to be given more attention in future studies. In addition
to providing a valuable tool for mechanistic studies, our aggregation assay might in the
future be used for diagnostic purposes to distinguish more clearly between benign Notch3
polymorphisms and pathogenic CADASIL mutants. The reported CADASIL cases carry-
ing cysteine-sparing mutations are rare in the literature, but maybe they have been so far
mostly overlooked due to the fact that CADASIL was originally characterized as a disease
caused by cysteine mutations. Future studies are required for a better understanding of
the role cysteine-sparing mutants play in CADASIL pathogenesis.
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3.2 Identiﬁcation of anti-aggregatory compounds
Since the vascular deposition of Notch3-ECD is a central determinant of CADASIL pathol-
ogy, preventing Notch3 aggregation is likely to represent a promising therapeutic approach.
One goal of this study was to evaluate whether our in vitro assay is suitable for the
identiﬁcation of Notch3 aggregation inhibitors. Bertsch et al. 104 had used SIFT for a
high-throughput screening of 10,000 drug-like compounds to identify lead structures for
anti-prion drugs. Compounds of the DPP class were found to be highly eﬀective and
Wagner et al. 98 tested a focused DPP library consisting of 150 compounds in vitro for the
inhibition of pathological PrP and -syn oligomer formation and further in cell culture and
in vivo animal models. They could identify anle138b as novel disease-modifying substance
that targets directly and speciﬁcally oligomeric forms of proteins. Based on this study we
investigated the eﬀect of 15 DPP-based compounds on Notch3 aggregation. We identiﬁed
six compounds with a high (> 80%) and three with a moderate (> 68%) ability to inhibit
de novo multimer formation. Anle138b showed no eﬀect at all, but the closely related
derivative anle138c was highly active. The six most potent inhibitors for Notch3 showed
similar eﬀects in the inhibition of -syn comparable to the results reported in Wagner
et al. 98 (Table 3.2).
Table 3.2: Eﬃciency of various DPP inhibitors on Notch3 and -syn aggregation in
the SIFT assay.
Compound % inhibition % inhibition
of Notch3 of -syna
sery105 94 95
sery166a 91 100
anle137c 91 100
sery106 91 97
anle136c 90 99
anle138c 88 100
sery159a 76 100
sery95 76 69
sery320a 68 ≤ 10
sery144 58 91
sery139 55 100
sery118 44 76
anle137b 27 ≤ 10
anle253b ≤10 50
anle138b ≤10 77
a A. Giese, unpublished data
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This raises the interesting possibility that DPP compounds can act on various kinds of
neurotoxic aggregates. However, Notch3 aggregates have so far been assumed to be struc-
turally diﬀerent from those formed by most other misfolded proteins, since they do not
consist of amyloid ﬁbrils and do not bind to certain chemical dyes such as Congo red and
thioﬂavinT. For anle138c and sery166a, two of the highly eﬀective compounds, we in addi-
tion obtained dose-response curves, which revealed that already concentrations of 0.3 M
are suﬃcient for signiﬁcant inhibition. These are important data for further therapeutic
studies, since lower concentrations are in a better agreement with the drug tolerance of
cells or living organisms.
Based on our data we performed a structure-activity analysis revealing that an inhibition
of > 40 % requires the presence of at least one OH group. However, this chemical group
seems to be necessary but not suﬃcient for eﬀective inhibition, other molecular features
may be crucial as well. Comparing the structure and hydrophobicity of anle138c, a potent
compound with an inhibition eﬃcacy of 90 %, and sery118 with an eﬃcacy of 44 %,
revealed that although their molecular composition is similar (Table 2.1), however the 3D
structure as well as the arrangement of hydrophobic and hydrophilic parts are diﬀerent
(Figure 3.1). This diversity may be important for binding to Notch3 and thus inhibiting
the aggregation process.
anle138c
sery118
Molecular lipophilicity potential (MLP) 3D tube model
Figure 3.1: Structural details of anle138c and sery118. Structures of both compounds are
displayed as 3D tube model with atoms in diﬀerent colors: grey = C, white = H, red = O, blue
= N and pink = Br; and with their molecular lipophilicity potential (MLP): pink and blue dots =
hydrophobic surface, yellow and green dots = hydrophilic surface. MLP is calculated from atomic
hydrophobicity contribution. Structural models were created with molinspiration.com
To identify the exact binding site of protein and inhibitor, detailed structural analysis
will be required. However, the atomic resolution structure of the Notch3-ECD remains
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to be elucidated, which is a major challenge for drug development in the CADASIL ﬁeld.
Thus, our SIFT assay is an innovative approach for the drug identiﬁcation, since only low
concentrations of Notch3 are required and it is easy to screen for candidates for further
assessment. We provide proof-of-principle for the suitability of this assay to identify
aggregation inhibitors. In the future, systematic variations of the structure of eﬀective
inhibitors have to be performed to reveal a well-deﬁned structure-activity relationship as
it has been done in the work of Wagner et al. 98 . Since the identiﬁed eﬀective compounds
have a poor predicted bioavailability due to their OH groups, screening of additional
compound classes might be required. Furthermore, the results of our experiments have to
be validated with additional mutants including ones from other ECD regions.
Due to the apparently important role of OH groups for the inhibition of Notch3 aggre-
gation, we decided to investigate natural polyphenols, a group of compounds rich in OH
groups. They are abundant in food and beverages of plant origin and considered as respon-
sible for the observed beneﬁcial eﬀect of Mediterranean and Asian diets on cardiovascular
and neurodegenerative diseases.105 Several of them have been shown to inhibit the ag-
gregation of -syn in a SIFT assay.96,97 We selected 16 natural polyphenols as well as
BTE, a mixture of mostly polyphenolic compounds, to analyze their eﬀects on Notch3 ag-
gregation. Their overall inhibition rate was lower compared to the synthetic compounds.
Nevertheless, we could identify seven polyphenols and BTE with a signiﬁcant eﬀect, al-
though the overall inhibition rate was higher towards -syn aggregates (Table 3.3).96 The
three most eﬀective compounds in our assay were BTE (69 % inhibition), baicalein (68
% inhibition) and rosmarinic acid (66 % inhibition). However, since the bioavailability of
natural polyphenols is poor, they are not very well suited as therapeutic drugs. Intelligent
drug design and encapsulation strategies may overcome these negative eﬀects and retain
the characteristics of the natural product scaﬀold.
The diagnosis of CADASIL usually is made years after disease onset, when Notch3 deposits
have already been formed. Thus, antiaggregatory compounds that are able to resolve pre-
existing aggregates would be desirable. We therefore investigated the dissolution eﬃcacy
of selected synthetic as well as natural inhibitors and found that all compounds eﬀective
on the de novo aggregation also show dissolution potential, with the exception of BTE.
One possible explanation for this ﬁnding could be that binding of active BTE components
to Notch3-ECD monomers is rather unspeciﬁc preventing de novo aggregation but not
allowing aggregate dissolution. In contrast, the activity of all other identiﬁed active com-
pounds could thus be speciﬁc, an assumption supported by the ﬁnding that the kinetics of
compound-mediated dissolution are much slower in comparison to unspeciﬁc dissolution
with -ME and SDS.
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Table 3.3: Eﬃciency of various natural polyphenol inhibitors on Notch3 and -syn
aggregation in the SIFT assay. (-)-epigallocatechin gallate (EGCG)
Compound % inhibition % inhibition
of Notch3 of -syna
BTE 69 100
Baicalein 68 ∼ 97
Rosmarinic acid 66 55
Quercetin 57 88
Tannic acid 44 ∼ 98
Resveratrol 37 53
Morin 29 99
Gingkolide B 24 ∼ 92
Myricetin 24 90
EGCG ≤ 10 ∼ 93
Genistein ≤ 10 31
Apigenin ≤ 10 35
Purpurogallin ≤ 10 ∼ 46
a Caruana et al. 96
3.3 Validation of compounds in a novel ex vivo assay
Having identiﬁed several inhibitors in vitro, we aimed to validate them in a more complex
and thus physiological system. While a variety of studies have previously been performed
examining the eﬀect of CADASIL mutations on Notch3 ligand binding, signaling capacity
and actin organization56,106–110, no cell culture model allowing speciﬁcally the analysis
of Notch3 aggregation in a physiological setting is available. We therefore established an
assay system based on the incorporation of Notch3 fragments into the ECM by transiently
transfecting MEFs that produce a stable ECM after reaching conﬂuency with wt and
C183R mutant. Using diﬀerent buﬀers we were able to collect cell and matrix fraction
separately. Analyis by Western blotting revealed a strong enrichment of mutated but
not wt Notch3 in the ECM already two days after transfection. At day ﬁve bands of
higher molecular weight appeared, likely representing dimers and higher-order multimers
that could not be resolved under the applied reducing conditions. Immunoﬂuorescence
experiments conﬁrmed the mutant-depending Notch3 accumulation. Mutant but not wt
Notch3 could be detected in a dot-like structure pattern on ﬁbrillar structures which
showed partial co-localization with the ECM protein ﬁbronectin. This ﬁnding ruled out
an unspeciﬁc attachment of Notch3 fragments to the plastic surface of the culture dish
and suggested that the accumulation occurs in a focal manner, similar to the deposition
of GOM in human vascular material. Nevertheless, further experiments including co-
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localization studies with additional ECM proteins are required to ﬁnd out to what extent
these Notch3 deposits in cell culture correspond to in vivo aggregates.
Having shown that mutant Notch3 fragments accumulate in aggregate-like structures, we
treated the MEFs with three of the compounds with antiaggregatory activity in vitro.
Western blotting revealed a strong reduction of the Notch3 signal in the ECM fraction
upon treatment with anle138c and baicalein recapitulating the results from the SIFT as-
say. Anle138b, which had shown no eﬀect in vitro, also reduced the amount of Notch3
in the ECM, but to a much lesser extent. Whether this is the reason of diﬀerent com-
pound solubility in the aqueous buﬀer compared to the hydrophobicity of the matrix has
to be further investigated. The generation of stable cell lines constitutively expressing
the mutant Notch3 fragment would improve the comparability of the eﬀect of diﬀerent
compounds.
3.4 The future of CADASIL treatment approaches
Our inhibitor studies have yielded several compounds which can now be further studied,
e.g. in the mouse model PAC-Notch3 R169C, a well established preclinical CADASIL
model. The transgenic mice carry a P1-derived artiﬁcial chromosome (PAC) containing
the entire rat Notch3 locus with the R169C mutation resulting in a ∼ 4-fold overexpres-
sion of mutant Notch3.63 The ﬁrst pathological alterations the mice show are Notch3-ECD
accumulation (at one month of age) and GOM deposits (at ﬁve months of age) supporting
the view that Notch3 aggregation is the key determinant of CADASIL pathogenesis. At
higher age they develop several histological and functional symptoms of a microangiopathy
demonstrating that they can also serve as a model for functional analysis. Recently, Ghosh
et al. 111 described reduced microvascular reactivity and a reduction of pericytes in this
mouse model providing a hint for the underlying cellular pathomechanism. Furthermore,
Capone et al. 112 could prove that Timp3 and vitronectin, which are abnormally recruited
in Notch3-ECD-containing deposits, play a pathophysiological role in CADASIL. In ad-
dition to testing some of the identiﬁed compounds in vivo it might also be necessary in
the future to screen more compound classes with our in vitro assay to identify substances
with better medicinal chemistry features.
In addition to the antiaggregation approach the possibility of a vaccination as in the AD
ﬁeld is considered. Both active and passive immunization could be used and would also
allow a protective vaccination of asymptomatic individuals. However, the aggregating
protein Notch3-ECD is large and it is unclear which part of it should be targeted by an
antibody. Further, little is known about diﬀerences in the toxicity of diﬀerent Notch3
mutants. It would have to be evaluated whether one immunogen/antibody would be
suﬃcient for treatment of all CADASIL patients or whether several alternative treatments
would be necessary. Also, signiﬁcant targeting of endogenous wt Notch3, required for
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a variety of physiological processes, has to be avoided. Even more, the impact of the
immune response is generally hard to predict. In AD research, the vaccine AN-1792
used in an active immunization approach did not pass the phase II trial, since several
patients developed serious brain inﬂammation leading to a halt of the trial.113 In a passive
immunotherapy approach, no active antibody production would happen, however, it would
require regular applications to maintain the antibody levels. So far, no studies investigating
these diﬀerent kind of questions have been reported demonstrating that a lot of work is
still ahead to evaluate the applicability of the immunization approach.
An approach a little bit more advanced is the exon skipping approach suggested by Rut-
ten et al. 114 . Exon skipping is a therapeutic approach that uses antisense oligonucleotides
(AONs) to modify a protein on mRNA level either by restoring the open reading frame,
blocking gene expression, inducing alternative splicing sites or modifying the number of
exons. The most promising results using exon skipping have been achieved with Duchenne
muscular dystrophy (DMD) by skipping of an additional exon to restore the protein tran-
script and in spinal muscular atrophy (SMA) by directing AONs against a splice silencer
to include an additional exon.115 Rutten et al. 114 now proposed the exclusion of the mu-
tated Notch3 EGF-like domain by exon skipping to prevent Notch3 aggregation through
cysteine correction. This approach makes use of the fact that the majority of Notch3 exons
encode complete single EGF-like domains or combinations of them. Moreover, a variety
of exons and exon combinations are amenable for exon skipping due to the preservation
of the open reading frame. Rutten et al. 114 selected several exons and exon combinations
as targets, analyzed the structure of the corresponding truncated Notch3 proteins by in
silico studies and designed the appropriate AONs for modulating hnRNA splicing. They
could show that skipping occurs to signiﬁcant extent in cultured cells and that the trun-
cated proteins display normal processing, ligand binding and ligand-induced activation.
However, their aggregation behavior could not be comprehensively evaluated due to the
lack of an appropriate assay. To analyze this approach further, in vivo data from a mouse
model will be needed. Also the administration routes have to be evaluated. An alternative
AON-mediated approach is the reduction of full-length Notch3 expression in general with
the goal to reduce the amount of mutated receptor to a level no longer pathological. How-
ever, wt Notch3 would also be aﬀected and its expression levels would have to be tightly
controlled in treated cells and tissues.
In summary, several promising therapeutic approaches are considered for CADASIL treat-
ment, however, none of them has so far reached a stadium approaching clinical applica-
tion. A number of future studies are required to investigate the applicability, eﬃciency
and safety of the diﬀerent approaches. But with our initial studies on drug-mediated inhi-
bition of Notch3 aggregation we have laid the groundwork for an anti-aggregation therapy
that might some day be applied to CADASIL patients.
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4 Material and methods
4.1 Equipment
CO2 incubator HeraCell Heraeus
Coﬀee machine DeLonghi Nespresso
Incubation shaking cabinet Certomat BS-1 Sartorius
Insight Research Reader Evotec Biosystems
Magnetic stirrer KMO 2 basic IKA
Magnetic stirrer RCT basic safety control IKA
Magnetic stirrer RH basic 2 IKA
Microscope Axiovert 200M Zeiss
Microscope imaging system AxioCam MRm Zeiss
Microscope Wilovert S Hund Wetzlar
Multi imaging system Fusion FX7 Vilber Lourmat
Oven Thermocenter TC 40/100 Salvis Lab
Overhead shaker Reax 2 Heidolph
PCR machine PTC-200 MJ Research
pH-electrode BlueLine Schott Instruments
pH-meter Lab 850 Schott Instruments
Pipettor Pipetboy Integra
Plate reader Multiskan RC Thermo Lab Systems
Power supply Power Pac 200 BioRad
Power supply Power Pac 300 BioRad
Power supply Power Pac HC BioRad
Precision analytical balance ALC-80.4 Acculab
Rotator 2-1175 neoLab
Shaker ST 5 Ingenieurbüro CAT
Spectrophotometer Nanodrop ND-1000 peqlab
Thermo shaker MKR 23 HLC by Ditabis
Thermo shaker Thriller peqlab
Thermo shaker Ts-100 Biosan
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Ultracentrifuge Optima MAX-XP (TLA-55 rotor) Beckman Coulter
Vacuum pump BVC 21 Vacuubrand
Vacuum pump BVC control Vacuubrand
Vortex Genie 2 Scientiﬁc Industries
Water bath 1005 GFL
Water puriﬁcation system Milli-Q (Q-POD) Millipore
15 ml Falcon VWR
24-well cell culture dishes BD Falcon
384-well Sensoplate plus, PS, glass bottom Greiner Bio-One
50 ml Falcon BD Falcon
6-well cell culture dishes Omnilab
Biosphere ﬁltertips, extralong (200 l, 1250 l) Sarstedt
Cell culture ﬂasks 25 cm2 Sigma
Cell scraper BD Bioscience
Centrifuge tubes 1.5 ml Beckman Coulter
Coverslips, round ? 18 mm Thermo Scientiﬁc
Filtertips 10 l (0.1 - 10 l ) G short peqlab
Filtertips 10 l (0.5 - 10 l ) E long peqlab
Microscope slide Menzel Gläser Superfrost Plus Thermo Scientiﬁc
Multiﬂex Round Tips Pipettenspitzen 0.5- 200 l peqlab
Nunclon Surface Triple Flasks 500 cm2 Nunc
PCR tubes ﬂat cap 0.2 l peqlab
Protein LoBind Tubes (0.5 ml, 1.5 ml) Eppendorf
SafeGuard Filtertips (0.1 - 10 l G, 20 l, 1000 l) peqlab
SafeGuard Filtertips (1-200 l) peqlab
Safe-Lock Tubes (0.5 ml, 1.5 ml; 2.0 ml) Eppendorf
Sterile disposable pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml) Sarstedt
Syringe Injekt-F 25G Braun
TipOne 10 l XL Graduated Tips StarLab
TipOne 1000 l Blue Graduated Tips StarLab
TipOne 200 l Yellow Bevelled Tips StarLab
Tissue culture ﬂasks T-80 Nunc
4.2 Chemicals
Acrylamide (Ultra Pure Proto Gel 30%) National diagnostics
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Agar Invitrogen
Agarose Sigma
Aluminium sulfate hydrate Sigma
Ammonium persulfate (APS) Sigma
Ampicillin Sigma
Bovine serum albumin (BSA) Sigma
Boric acid Roth
Bromophenol blue Sigma
Coomassie Brilliant Blue G250 Fluka
Dimethyl sulfoxide (DMSO) Merck
Deoxycholic acid (DOC) Sigma
Dithiothreitol (DTT) Sigma
Ethylenediaminetetraacetic acid (EDTA) Roth
Ethanol Merck
Glycerol Roth
Glycine Merck
Double distilled water (H2Obidest) generated with MiliQ puriﬁcation system
HCl Roth
K2HPO4 Merck
KCl Merck
Methanol Merck
Mowiol 4-88 Roth
NaCl Roth
NaH2HPO4 Roth
NaN3 Merck
NH3 Merck
NP-40 Fluka
Orange G Sigma
Ortho-phosphoric acid Roth
Paraformaldehyde (PFA) Roth
Peptone from Casein Serva
Skim milk powder Fluka
Sodium dodecyl sulfate (SDS) Serva
Sodium bicarbonate Sigma
Tetramethyletylenediamine (TEMED) Bio-Rad
Tris(hydroxymethyl)aminoethane (Tris), Trizma R⃝ base Sigma
Tris HCl Roth
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Triton X-100 Sigma
Tween-20 Merck
Xylene Cyanole ICN
Yeast extract Roth
4.3 DNA methods
4.3.1 Plasmids
In Table 4.3 all plasmids are listed that were used in this thesis. Table 4.4 shows details
of the plasmids constructed in this thesis.
Table 4.3: List of plasmids. Details about vectors and inserts as well as sources/references
(Ref.) of each plasmid are given. (1) a kind gift of Y. Durocher (National Research Council,
Quebec, Canada), (2) Promega, (3) Duering et al. 71 , (4) Table 4.4 in this thesis.
Name Description Ref.
pTT5 high yield mammalian protein expression vector (1)
pFC14A Halo-Tag mammalian protein expression vector (2)
pTT5/hN3-EGF1-5-wt-myc encodes hNotch3 EGF1-5 wt fused to a myc-His tag (3)
pTT5/hN3-EGF1-5-75-myc contains the mutation R75P in human Notch3 (4)
pTT5/hN3-EGF1-5-133-myc contains the mutation R133C in human Notch3 (3)
pTT5/hN3-EGF1-5-183-myc contains the mutation C183R in human Notch3 (3)
pTT5/hN3-EGF1-5-212-myc contains the mutation C212Y in human Notch3 (4)
pTT5/hN3-EGF1-5-213-myc contains the mutation R213K in human Notch3 (4)
pFC14A/hN3-EGF1-5-wt-Halo encodes hNotch3 EGF1-5 wt fused to a HaloTag (4)
pTT5/hN3-EGF1-5-wt-Halo encodes hNotch3 EGF1-5 wt fused to a HaloTag (4)
pTT5/hN3-EGF1-5-del-Halo contains the deletion 88AGRV91 in human Notch3 (4)
pTT/hN3-EGF1-5-61-Halo contains the mutation R61W in human Notch3 (4)
pTT/hN3-EGF1-5-75-Halo contains the mutation R75P in human Notch3 (4)
pTT/hN3-EGF1-5-80-Halo contains the mutation D80G in human Notch3 (4)
pTT/hN3-EGF1-5-113-Halo contains the mutation R113Q in human Notch3 (4)
pTT/hN3-EGF1-5-133-Halo contains the mutation R133C in human Notch3 (4)
pTT/hN3-EGF1-5-170-Halo contains the mutation H170R in human Notch3 (4)
pTT/hN3-EGF1-5-179-Halo contains the mutation G179V in human Notch3 (4)
pTT/hN3-EGF1-5-183-Halo contains the mutation C183R in human Notch3 (4)
pTT/hN3-EGF1-5-212-Halo contains the mutation C212Y in human Notch3 (4)
pTT/hN3-EGF1-5-213-Halo contains the mutation R213K in human Notch3 (4)
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Table 4.4: DNA constructs generated in this thesis. Primers (Table 4.5)/inserts, templates
and restriction sites for used constructs are listed. Methods used for construct generation are
described in section 4.3.3. Polymerase chain reaction (PCR) performed according to the manufac-
turer’s protocol. (SM) site-directed mutagenesis PCR, (SMK) QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent): , (SC) sub-cloning: inserts were cut out from template and inserted
into the new vector, (S) standard PCR, (LD) loop-deletion PCR, * performed by Caroline Prell
(Institute for stroke and dementia research (ISD), Munich, Germany).
Name Primers or inserts Template Restriction Generation
enzymes
pTT5/hN3-EGF1-
5-75-myc
N3-65-F/R75P-R, N3-
430-R
pTT5/hN3-EGF1-
5-wt-myc
BbvCI/NheI (SM) *
pTT5/hN3-EGF1-
5-212-myc
N3-C212Y-F/N3-
C212Y-R
pTT5/hN3-EGF1-
5-wt-myc
— (SMK) *
pTT5/hN3-EGF1-
5-213-myc
R213K-F/N3-739-R,
N3-351-F
pTT5/hN3-EGF1-
5-wt-myc
BbvCI/XbaI (SM) *
pFC14A/hN3-
EGF1-5-wt-Halo
SP+AsiSI-
F/EGF5+XhoI-R
pTT5/EGF1-5-wt-
myc
AsiSI/XhoI (S)
pTT5/hN3-EGF1-
5-wt-Halo
Halo-F/Halo-R pFC14A AgeI/XbaI (S)
pTT5/hN3-EGF1-
5-del-Halo
del-1,3-F/del-1-R, del-
2-F/del-2,3-R
pTT5/hN3-EGF1-
5-wt-Halo
NaeI/XbaI (LD)
pTT/hN3-EGF1-5-
61-Halo
113-1-F/61-1-R, 113-2-
R
pTT5/hN3-EGF1-
5-wt-Halo
NheI/SbfI (SM)
pTT5/hN3-EGF1-
5-75-Halo
hN3 EGF1-5 R75P pTT5/hN3-EGF1-
5-75-myc
SpeI/XbaI (SC)
pTT5/hN3-EGF1-
5-80-Halo
113-1-F/80-1-R, 113-2-
R
pTT5/hN3-EGF1-
5-wt-Halo
NheI/SbfI (SM)
pTT5/hN3-EGF1-
5-113-Halo
113-1-F/113-1-R, 113-
2-R
pTT5/hN3-EGF1-
5-wt-Halo
NheI/SbfI (SM)
pTT5/hN3-EGF1-
5-133-Halo
hN3 EGF1-5 R133C pTT5/hN3-EGF1-
5-133-myc
SpeI/XbaI (SC)
pTT/hN3-EGF1-5-
170-Halo
170-1-F/170-1-R, 170-
2-R
pTT5/hN3-EGF1-
5-wt-Halo
BbvCI/XbaI (SM)
pTT5/hN3-EGF1-
5-179-Halo
170-1-F/179-1-R, 170-
2-R
pTT5/hN3-EGF1-
5-wt-Halo
BbvCI/XbaI (SM)
pTT5/hN3-EGF1-
5-212-Halo
hN3 EGF1-5 C212Y pTT5/hN3-EGF1-
5-212-myc
SpeI/XbaI (SC)
pTT5/hN3-EGF1-
5-213-Halo
hN3 EGF1-5 R213K pTT5/hN3-EGF1-
5-213-myc
SpeI/XbaI (SC)
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4.3.2 Oligonucleotides
Table 4.5 lists the oligonucleotides used for PCR.
Table 4.5: List of oligonucleotides Mutations for site-directed mutagenesis PCR are marked in
red. All oligonucleotides were designed with CLCMainWorkbench and manufactured by Metabion,
Martinsried, Germany.
Name Sequence
N3-65-F 5’-CACCCGTGCGGGCGCT-3’
R75P-R 5’-CTGACACGGCTCACCC-3’
N3-C212Y-F 5’-ACGGGGGCACCTACAGGCAGAGTGG-3’
N3-C212Y-R 5’-CCACTCTGCCTGTAGGTGCCCCCGT-3’
R213K-F 5’-ACCTGCAAGCAGAGTG-3’
N3-739-R 5’-TGAGTTTTTGTTCGAAGGG-3’
N-351-F 5’-CTCCCTGCCAGATCCCTG-3’
SP+AsiSI-F 5’-ACATCCGGCGATCGCGTTCAGCCTGGTTAAGTC-3’
EGF5+XhoI-R 5’-CTATCCGCTCGAGTTCACAATTCTGACCCTCAAAC-3’
Halo-F 5’-ATCGCTCTAGACCAACCACTGAGGATCTG-3’
Halo-R 5’-CTAGCACCGGTCTATTAACCGGAAATCTCC-3’
del1,3-F 5’-CATCCACTTTGCCTTTCTCTCC-3’
del-1-R 5’-CTGGCAGACACAGGGGCCTGAGTGAC-3’
del-2-F 5’-CCCCTGTGTCTGCCAGAGTTCAGTGG-3’
del-2,3-R 5’-TAGGAGGAGGTCGGGTTACC-3’
61-1-R 5’-CTCCCAGGAGGGCAGCTG-3’
80-1-R 5’-ACAGGGGCCCTCCAGCTG-3’
113-1-F 5’-CCCTGCTGCTGCTGCTAG-3’
113-1-R 5’-AGCAGTCAGGGCCTTGGAAGCCA-3’
113-2-R 5’-ACACGTTCACTTCACAATTCTGACCCTCAA-3’
170-1-F 5’-ATTCTCATGCCGGTGCCC-3’
170-1-R 5’-ACCACGGCGGCAGGGCTCAC-3’
170-2-R 5’-ACGTAGGAGGAGGTCGGGTTACCGTGCAGGAACA-3’
179-1-R 5’-CGGAAGGAGACAGGTGTGTT-3’
4.3.3 PCR
Standard PCR
Standard PCR was performed to amplify a certain DNA sequence using the following
components (Table 4.6):
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Table 4.6: Standard PCR reaction mix
Component Volume
native Pfu polymerase buﬀer (10x) 5 l
Q-solution (5x) (Quiagen) 10 l
template (100 ng/l) 0.5 l
dNTP-mix (10 M) 1 l
forward primer (10 M) 2.5 l
reverse primer (10 M) 2.5 l
native Pfu polymerase 1 l
Taq polymerase 0.1 l
H2Obidest ad 50 l
All components were pipetted on ice. Reaction was performed in a Thermocycler using
the following program (Table 4.7):
Table 4.7: PCR program. Annealing temperature depends on primer pair that was used.
Step Temperature Periode
Denaturation 94◦C 3 min
30 cycles:
Denaturation 94◦C 30 sec
Annealing 52− 62◦C 1 min
Elongation 72◦C 1 min/1000 bp
Elongation 72◦C 10 min
Storage 4◦C ∞
PCR products were puriﬁed using the QIAquick PCR Puriﬁcation Kit (Qiagen) according
to the manufacturer’s protocol.
Site-directed mutagenesis PCR
Mutations were inserted within the ﬁrst PCR step (Table 4.6 and Table 4.7), whereas one
primer contains the desired point mutation. After puriﬁcation of the ﬁrst PCR product
(see section 4.3.4) this fragment served as megaprimer for the second PCR step, which
ﬁnally includes an appropriate restriction site. Final concentration of the megaprimer
used for the second step was 0.2 M.
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Loop-deletion PCR
Two PCR steps were performed to amplify the 5’ and the 3’ end of the desired fragment
with primers containing an internal overlap after the deletion. After puriﬁcation (see
section 4.3.5) both PCR products served as template for the third PCR step.
4.3.4 Agarose gel electrophoresis
TBE-Buﬀer:
89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.0
Agarose gels:
0.5-2% (w/V) agarose melted in TBE-Buﬀer, 1:10000 SYBRtextregistered Safe DNA Gel Stain (Invitrogen)
DNA loading buﬀer (6x):
60% glycerol, 10 mM Tris HCl, 60 mM EDTA, 0.025% (w/v) Xylene Cyanol, 0.025% (w/v) Orange G, pH 7.6
DNA was separated in 0.5-2% agarose gels, depending on the desired fragment sizes.
Electrophoresis was performed in TBE-buﬀer using the PerfectBlue gelsystems (peqlab)
with a constant voltage of 80 V (small chamber) or 100 V (large chamber). As molecular
marker, PeqGOLD 50 bp DNA ladder (up to 1 kb, peqlab) or PeqGOLD DNA ladder mix
(up to 10 kb, peqlab) was used respectively.
4.3.5 DNA restriction
Preparative restriction for subsequent ligation (see section 4.3.7) contains the following
components (Table 4.8.)
Table 4.8: Preparative DNA restriction. Used restriction enzymes are listed in Ta-
ble 4.4, column Restriction. All enzymes are purchased from NEB. Appropriate restriction en-
zyme buﬀer for double digestion was evaluated by the NEB homepage (https://www.neb.com/
tools-and-resources/interactive-tools/double-digest-finder).
Component Amount
restriction enzyme 1 10 U
restriction enzyme 2 10 U
DNA 1 g
BSA 10x (opt.) 2 l
Restriction enzyme buﬀer 10x 2 l
H2Obidest ad 20 l
New ligated plasmids were analyzed for correct insertion by analytic restriction using the
following reaction mix (Table 4.9).
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Table 4.9: Analytic DNA restriction.
Component Amount
restriction enzyme 1 5 U
restriction enzyme 2 5 U
DNA 0.5 g
BSA 10x (opt.) 2 l
Restriction enzyme buﬀer 10x 2 l
H2Obidest ad 20 l
Mixtures were incubated for 1h at 37◦C. Restriction enzymes were, if recommended,
heat inactivated at 65◦C for 30 min. PCR fragments were isolated with agarose gel elec-
trophoresis (see section 4.3.4), excised and puriﬁed with the GeneJET Gel Extraction Kit
(Fermentas) according to the manufacturer’s protocol .
4.3.6 Vector dephosphorylation
To avoid religation, vector DNA was dephosporylated adding 1 l Antarctic phosphatase
(NEB), 3 l Antarctic phosphatase buﬀer and 6 l H2Obidest to the DNA restriction mix
(see section 4.3.5) and incubated for 30 min at 37◦C.
4.3.7 Ligation
50 ng of vector was mixed with a threefold excess of insert, 1 l T4 DNA ligase (NEB), 2
l ligase buﬀer and H2Obidest up to a volume of 20 l. The mixture was incubated for 1
h at room temperature (RT).
4.3.8 Transformation of competent bacteria
Lysogeny broth medium (LB medium):
1% (w/v) peptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, pH 7.0
LBamp medium:
LB medium, 100 g/ml ampicillin
LBamp agar plates:
LBamp medium, 1.5% (w/v) agar
2 l of ligation mix or 100 ng of DNA plasmid to be ampliﬁed was added to competent
E.coli (DH5) respectively. Bacteria were incubated on ice for 30 min, heat shocked at
42◦C for 90 sec and kept on ice for another 2 min. 300 l LB medium were added and
bacteria suspension shaken for 1 h at 37◦C. Bacteria were plated on LBamp agar plates
and incubated o/n at 37◦C. Colonies were picked and inoculated in fresh LBAMP medium,
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volume depending on the plasmid isolation method (see section 4.3.9) and cultivated o/n
at 37◦C shaking at 230 rpm.
4.3.9 DNA isolation
For small-scale DNA isolation, transformed bacteria (see section 4.3.8) were grown in 4 mL
LBamp medium o/n. Plasmids were isolated using the NucleoSpin Plasmid kit (Macherey-
Nagel) according to the manufacturer’s protocol. Large amount of plasmids were isolated
from 300 ml o/n culture in LBamp using the NucleoBond Xtra Midi kit (Macherey-Nagel)
according to the manufacturer’s protocol. DNA concentration was measured with Nan-
oDrop ND-1000 (peqlab). Plasmid isolation control was done by test restriction using
the appropriate restriction enzymes (see section 4.3.5) and subsequent agarose gel elec-
trophoresis (see section 4.3.4). DNA was sent for sequencing to GATC Biotech AG (Kon-
stanz, Germany).
4.4 Cell culture
4.4.1 Cell lines
Table 4.10: Cell lines. Sources: (1) Y. Durocher (National research Council, Quebec, Canada),
(2) Eva Scharrer (ISD, Munich, Germany), isolated from 14.5-dpc embryos of C57BL/6J mice,
immortalized through serial passaging
Cell line Description Source
HEK293E human embryonic kidney cells (1)
wt1o mouse embryonic ﬁbroblasts (2)
wt2o mouse embryonic ﬁbroblasts (2)
wt1 mouse embryonic ﬁbroblasts (2)
wt3 mouse embryonic ﬁbroblasts (2)
wt4 mouse embryonic ﬁbroblasts (2)
4.4.2 Cell cultivation
Phosphate buﬀered saline (PBS):
154 mM NaCl, 9.5 mM NaH2HPO4 x 2 H2O, 1.7 mM K2HPO4, pH 7.4
0.05% Trypsin-EDTA 1x (Gibco, Life Technologies)
Medium:
Dulbecco’s Modiﬁed Eagle Medium (DMEM) High Glucose GlutaMAXTM Supplement, pyruvate (Gibco, Life Tech-
nologies)
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Supplements:
Fetal bovine serum (FBS) (Gibco, Life Technologies)
penicillin/streptomycin solution (p/s) (100 U/ml penicillin, 100 g/ml streptomycin) (Gibco, Life Technologies)
25 g/ml G418 sulfate, geneticin (G418) (Merck)
Cells were cultured in DMEM supplemented with 10% FBS at 37◦C in the presence of
5% CO2. To HEK293E medium G418 was added for selection. MEFs were kept with
p/s. For passaging, cells were washed with PBS and trypsinized for 3 min. Trypsin was
inactivated by adding fresh medium. Cells were centrifuged for 7 min at 400 g. Cell pellet
was resuspended and an appropriate amount of cells were seeded in fresh medium. Cells
were tested for mycoplasma on regular basis using the Venor GeM OneStep kit (Minerva
Biolabs) or the MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza).
4.4.3 Cell transfection
Polyethylenimine (PEI) transfection
HEK293E cells were cultivated until a conﬂuence of 70%. Standard medium (see section
4.4.2) was changed to DMEM with 2.5% FBS. DNA was mixed with OptiMEM (Gibco,
Life Technologies) and PEI (Polysciences Europe) was added subsequently. Amounts of
all components are listed in Table 4.11. Transfection mix was incubated for 25 min at RT
and added to the cells. Tranfection medium was changed 24 h later to DMEM.
Table 4.11: Tranfection mixtures for PEI.
Culture dish Medium DNA PEI (1mg/mL) OptiMEM
6-well 1 ml 2 g 8 l ad 200 l
T-80 ﬂask 10 ml 12 g 48 l ad 1.2 ml
500 cm2 ﬂask 90 ml 75 g 300 l ad 3 ml
Lipofectamine2000 transfection
MEF cells were seeded to reach 90% conﬂuency the day of transfection. Then medium was
changed to DMEM with 10% FBS. First, DNA and Lipofectamine 2000 (Life Technologies)
were mixed separately with OptiMEM and incubated for 5 min at RT. Amounts of all
components are listed in Table 4.12. Both mixtures were combined and further incubated
for 20 min at RT and added to the cells. Transfection medium was changed 5 h later to
DMEM with 10% FBS and p/s .
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Table 4.12: Tranfection mixtures for Lipofectamine 2000.
Culture dish Cells OptiMEM DNA Lipofectamine 2000
24-well 0.5x105 500 l 2x 25 l 0.5 g 2 l
6-well 2.5x105 2 ml 2x 100 l 2.5 g 10 l
T-80 ﬂask 2x106 10 ml 2x 750 l 25 g 80 l
4.4.4 Cryoconservation
Freezing medium:
FBS with 10% DMSO
Cells were passaged (see section 4.4.2). Pellet was resuspended in an appropriate volume
of freezing medium, transferred into a freezing container, slowly frozen o/n at −80◦C and
ﬁnally transferred into a liquid-nitrogen tank.
4.5 Protein analysis
4.5.1 Antibodies
All antibodies used in this work are listed in Table 4.13 and Table 4.14.
Table 4.13: List of primary antibodies. IB: immunoblot, IF: immunﬂuorescence;
the monoclonal anti-Notch3 (3G6) antibody was raised against the peptide sequence
129AHGARCSVGPDGRFLCSC146 of human Notch3.
Antibody Type Application Source
anti-Fibronectin (FN-3E2) mouse monoclonal IB 1:1000 Sigma
anti-Fibronectin (N-20) goat polyclonal IF 1:100 Santa Cruz
anti-myc (9E10) mouse monoclonal IB 1:4000 Hybridoma Bank,Iowa, USA
IF 1:1000
anti-Notch3 (3G6) rat monoclonal IB 1:2000 E.Kremmer, Helmholtz Zentrum,
anti-PDGFR goat polyclonal IB 1:5000 R&D
anti-Tubulin (2-28-33) mouse monoclonal IB 1:2000 Sigma
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Table 4.14: List of secondary antibodies. Secondary antibodies for immunoblots were used
in a 1:10000 dilution, for immunoﬂuorescence in a 1:100 dilution. Horseradish peroxidase (HRP)
Antibody Coupled to Source
goat anti-mouse HRP Dako
rabbit anti-goat HRP Jackson
rabbit anti-rat HRP Dako
donkey anti-goat Rhodamine Red-x Jackson
donkey anti-mouse Cy2 Jackson
4.5.2 Total protein lysate
PBS:
154 mM NaCl, 9.5 mM NaH2HPO4 x 2 H2O, 1.7 mM K2HPO4, pH 7.4
10x protease inhibitor (PI):
1 complete protease inhibitor cocktail EDTA-free tablet (Roche) in 1 ml H2Obidest
Tris-HCl, NaCl, Tween (TNT) lysis buﬀer:
50 mM Tris-HCl, 200 mM NaCl, 0.5% NP-40, 1x PI, pH 8.0
24 h after PEI-transfection of HEK293E cells in 6-well culture dishes (see section 4.4.3)
medium was changed to 1 ml DMEM without FBS. At indicated time points, conditioned
medium was taken oﬀ for analysis and centrifuged for 5 min at 1000 g to remove dead
cells. Cells were washed with PBS and resuspended in 1 ml PBS. Cell resuspension was
centrifuged for 5 min at 1000 g, supernatant was removed and cell pellet was lysed in
100 l TNT lysis buﬀer and incubated on ice for 20 min. Cell debris was removed by
centrifugation for 30 min at 14000 g and 4◦C. Protein concentration was measured using
the BCA Protein Assay Kit (Thermo Scientiﬁc Pierce) according to the manufacturer’s
standard protocol. Brieﬂy, 10 l of BSA standard or (diluted) sample were mixed with
80 l of working solution in a 96-well reaction plate (peqlab) and incubated for 30 min at
37◦C. Absorbance at 562 nm was measured with a Multiscan RC plate reader (Thermo
Labsystems). Standards and samples were measured in duplicates.
4.5.3 Matrix isolation
PBS:
154 mM NaCl, 9.5 mM NaH2HPO4 x 2 H2O, 1.7 mM K2HPO4, pH 7.4
10x PI:
1 complete protease inhibitor cocktail EDTA-free tablet (Roche) in 1 ml H2Obidest
Buﬀer M1:
0.1% Triton, 20 mM NH3, 1x PI in PBS
Buﬀer M2:
10 mM Tris, 150 mM Nacl, 0.5% DOC, pH 7.5
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Buﬀer M3:
2 mM Tris pH 7.5
Buﬀer M4:
10 mM Tris, 150 mM Nacl, 1% SDS, pH 7.5
MEFs were grown in 6-well culture dishes for 2 days after transfection (see section 4.4.3).
Then medium was changed to DMEM without FBS. Another 3 days later conditioned
medium was removed for analysis and centrifuged for 5 min at 1000 g to remove dead
cells. Cells were washed with PBS and cell bodies were lysed with 500 l buﬀer M1 at
RT by slowly shaking the wells. Cell lysates were carefully taken oﬀ and centrifuged at
16,000 g for 30 min at 4◦C to remove cell debris. Meanwhile, wells were cleared from cell
debris and nuclei by washing with 500 l buﬀer M2 for 10 min at 4◦C and shortly with
500 l hypotonic buﬀer M3. ECM was recovered in 250 l buﬀer M4 using a cell scraper
for removing everything from the wells and homogenized by passing the samples several
times through a 25G syringe. Protein concentration of the M4 fraction was measured using
the BCA Protein Assay Kit (Thermo Scientiﬁc Pierce) according to the manufacturer’s
enhanced protocol. Diﬀerent to the procedure described in section 4.5.2, the enhanced
BSA standard was used and the samples were incubated at 60◦C for 30 min.
4.5.4 Protein puriﬁcation
PBS:
154 mM NaCl, 9.5 mM NaH2HPO4 x 2 H2O, 1.7 mM K2HPO4, pH 7.4
Washing solution:
2% sodium bicarbonate, 1 mM EDTA
Dialysis buﬀer 1:
0.5x PBS
Dialysis buﬀer 2:
0.5x PBS, 200 mM NaCl
Puriﬁcation buﬀer:
PBS, 0.01% NP-40
Cleavage solution:
60 l TEV protease (Promega) in 1 ml puriﬁcation buﬀer
Protein puriﬁcation was performed with the components of the HaloTag Protein Puriﬁ-
cation System (Promega) using a modiﬁed protocol. For puriﬁcation control, an aliquot
was collected after each step.
HEK293E cells were cultured and transfected in 4x 500 cm2 ﬂasks (see section 4.4.3). 24
h after tranfection medium was changed to 90 ml DMEM without FBS per ﬂask. 5 days
later medium was collected and centrifuged for 5 min at 1000 g to remove dead cells. 45 cm
of Visking dialysis tubings (Type 27/32 inch, Roth) for each cell ﬂask were washed in 80◦C
washing solution for 30 min and rinsed with clear water afterward. Medium was dialyzed
against dialysis buﬀer 1 for 2x 2 h at RT and subsequently against dialysis buﬀer 2 for 3x
1-2 h at 4◦C. Meanwhile, 3 ml of thoroughly resuspended HaloLink Resin (375 l per 90
ml medium of one ﬂask) was spun at 1000 g for 5 min at RT. Supernatant was discarded
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and settled beads were equilibrated washing 3 times with 10 ml puriﬁcation buﬀer and
subsequent centrifugation at 1000 g for 5 min at RT. Finally, beads were resuspended in
the original volume of 3 ml. Medium was portioned into 50 mL falcons, supplemented with
0.01% NP-40 and HaloLink Resin was distributed equally to the falcons. Medium/beads
suspension was mixed o/n on a end-over-end tube rotator at 4◦C. The next day beads
were centrifuged for 5 min at 1000 g and supernatant was discarded. Beads were washed
three times with 10 ml puriﬁcation buﬀer and subsequently centrifuged for 5 min at 1000
g. Settled beads were resuspended in 1 ml cleavage solution containing TEV protease.
Suspension was incubated for 1 h at RT on a turning wheel. Beads were centrifuged for 5
min at 1000 g and supernatant was collected. Beads were washed with 1 ml puriﬁcation
buﬀer, centrifuged again for 5 min at 1000 g and supernatant was collected and pooled with
the former supernatant. To remove the TEV protease 50 l HisLink Resin was added and
suspension was incubated for 30 min at RT on a turning wheel. Beads were centrifuged for
5 min at 1000 g and protein solution was collected in LoBind tubes. Beads were washed
with 100 l puriﬁcation solution, spun again at 1000 g for 5 min and second fraction
was collected containing remaining protein. Protein concentration of both fractions was
determined using the BCA Protein Assay Kit (Thermo Scientiﬁc Pierce) according to the
manufacturer’s enhanced protocol (as described in section 4.5.3).
4.5.5 SDS-PAGE
4x Lower-Tris buﬀer:
1.5 M Tris, 0.4% SDS in H2Obidest, pH 8.8
4x Upper-Tris buﬀer:
0.5 M Tris, 0.4% (w/v) SDS in H2Obidest, 6.8
1x Running buﬀer:
25 mM Tris, 192 mM glycine, 1% (w/v) SDS in H2Obidest
5x Loading buﬀer:
375 mM Tris, 30% glycerol, 6% (w/v) SDS, 500 mM DTT, 0.03% (w/v) bromophenol blue in H2Obidest, pH 6.8
SDS-polyacrylamide gel electrophoresis (PAGE) was performed under denaturing and re-
ducing conditions with the Mini Format Electrophoresis System (Bio-Rad). Gels were
prepared due to the discontinous system. Composition of stacking and separation gels is
shown in Table 4.15.
Protein samples were mixed with 5x loading buﬀer and boiled for 5 min at 95◦C, except
ECM samples in buﬀer M4 (see section 4.5.3). To prevent aggregation of matrix proteins,
ECMsamples were incubated for 30 min at 45◦C. Samples were run together with the
Precision Plus Protein Standard All Blue (Bio-Rad) as molecular weight marker. Elec-
trophoresis was carried out at constant 80 V, followed by constant 120 V once proteins
were migrated into the separating gel. For protein detection, gels were ﬁrst stained with
Imperial Protein Stain (Thermo Fischer) and afterwards with Roti-Black P (Roth) for
silver staining, both according to the manufacturer’s protocol.
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Table 4.15: Composition of separating and stacking SDS polyacrylamide gels. Volumes
indicated are suﬃcient for 2 1.0 mm thick mini-gels.
Solution 5% Separating gel 10% Separating gel Stacking gel
4x Lower-Tris buﬀer 3 ml 3 ml
4x Upper-Tris buﬀer 1.02 ml
H2Obidest 6.88 ml 4.88 ml 2.94 ml
Acrylamide 2 ml 4 ml 0.56 ml
TEMED 10 l 10 L 4.5 l
10% APS 100 l 100 l 45 l
4.5.6 Western blot
1x Transfer buﬀer:
125 mM Tris, 1 M glycine, 20% methanol
Coomassie brilliant blue (CBB)-solution:
5% (w/v) Aluminium sulfate hydrate, 10% ethanol, 0.02% (w/v) Coomassie Brilliant Blue G250, 2% ortho-phosporic
acid
1x TBS-T buﬀer:
10 mM Tris, 150 mM NaCl, 0.05% Tween-20 in H2Obidest
Blocking solution:
4% (w/v) skim milk powder in 1x TBS-T buﬀer
PBS:
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 x 2 H2O, 2 mM KH2PO4, pH = 7.4
Proteins were transferred to a Immobilon-P Transfer polyvinylidene ﬂuoride (PVDF) mem-
brane (Milipore) using the Trans Blot SD semi dry transfer cell (Bio-Rad). PVDF mem-
brane was activated shortly in 100% methanol and then washed with transfer buﬀer. SDS
gel and membrane were stacked between extra thick blot paper (Bio-Rad) soaked with
transfer buﬀer. Transfer was performed for 1 h at constant 125 mA per membrane. After
transfer, membrane was stained with Ponceau-S solution (Sigma) and gel with CBB-
solution for loading and transfer control. Membrane staining was partly removed washing
with H2Obidest and membrane was blocked for 1 h in blocking solution. Blocked membrane
was incubated with primary antibody diluted in blocking solution (see section 4.5.1) for
1 h at RT or o/n at 4◦C, washed 3 times for 10 min with TBS-T and incubated for 1 h
at RT with the appropriate secondary antibody conjugated to HRP (see section 4.5.1).
Membrane was washed again 3 times for 10 min with TBS-T and 2 times with PBS.
Immobilon Western (Millipore) was added on top of the membrane as chemiluminescent
HRP substrate according to the manufacturer’s protocol and signal was detected at the
Fusion FX7 (Vilber-Lourmat).
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4.5.7 Immunoﬂuorescence
PBS:
154 mM NaCl, 9.5 mM NaH2HPO4 x 2 H2O, 1.7 mM K2HPO4, pH 7.4
Fixation buﬀer:
4% PFA in PBS
Blocking solution:
1% BSA in PBS
Mowiol:
6 g glycerol, 2.4 g Mowiol 4-88, 6 mL H2Obidest, 12 mL 0.2 M Tris-HCl pH 8.5
MEFs were grown in 24-well dishes on coverslips for 2 days after transfection (see section
4.4.3). Then, medium was changed to 350 l DMEM without FBS. Conditioned medium
was removed after 3 days for Western blot analysis and centrifuged for 5 min at 1000 g to
remove dead cells. Cells on coverslips were ﬁxed for 10 min with ﬁxation buﬀer, washed
with PBS and blocked for 1 h at RT with blocking solution. Incubation with primary
antibody diluted in blocking solution (see section 4.5.1) was performed for 1 h at RT or
o/n at 4◦C in a humid chamber. Coverslips were washed with PBS and incubated in
secondary antibodies diluted in blocking solution for 1 h at RT. Coverslips were washed
in PBS, incubated for 10 min at RT in PBS diluted 4’6-diamidino-2-phenylindole (DAPI)
(1:4000), washed again with PBS, ﬁnally with H2Obidest and mounted with Mowiol on
cover glas. Samples were analyzed with a ﬂuorescent microscope Axiovert 200M (Zeiss).
4.6 Single molecule spectroscopy
4.6.1 Measurement setup
The setup of the Insight II Reader is comparable to a confocal microscope which directs
the beams of two laser with diﬀerent wavelengths into a focus of 1 ﬂ and images the
emitted photons of the excited ﬂuorophores for each channel separately.
The exciting radiation is provided by an argon-laser with a wavelength of 488 nm and
a helium-neon-laser with a wavelength of 633 nm. The beam of both lasers is initially
combined in a dichroic mirror, passes through the optionally activated beam scanner unit
and is focused by a water immersions objective with a high numerical aperture 150 m
above the glass bottom of a 384 well plate within the sample volume. The diameter of the
Argon-laser focus is about 0.5 m and is entirely projected within the 0.65 m diameter
of the Helium-Neon-laser.
The optionally activated beam scanner consists of a mirror set that oscillates with variable
frequency and amplitude. In this work a frequency of 50 Hz and an amplitude of 100 m
was chosen. Additionally the plate was moved 2000 m perpendicular to the oscillation
direction by a microstep motor. Thus, the focus is scanning through the sample in a
meander-like fashion with a resulting scanning speed of 10 mm/sec.
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The emitted photons of the excited ﬂuorescent dyes are collected by the same objective
and passed through the ﬁrst dichroic mirror, where the signal is separated from the laser
beam. The following pinhole with a diameter of 70 m blocks any ﬂuorescent light not
originating from the focal region, thus separating the signal from unspeciﬁc background.
Finally the signal consisting of two diﬀerent wavelengths is separated by another dichroic
mirror and is detected by two separate APDs. The measured signal is transferred to a
computer and can be analyzed with diﬀerent programs (see section 4.6.3).
4.6.2 Reader adjustment
To gain constant and reproducible results, excitation intensity, focus size and pinhole po-
sition have to be adjusted before measurement. Excitation power of the Argon-laser was
set to 200 W, of the Helium-Neon-laser to 300 W. As calibrator served a solution of
unconjugated Alexa488- and Alexa647 dye with known diﬀusion and emission properties.
By means of a shiftable camera the laser focus was positioned 150 m above the glass
bottom of the plate. For an optimal focus laser ﬁbers and pinhole position were adjusted
with the help of the FCS+Plus_control software (Evotech). As adjustment parameter
served counts per particle (CPP), indicating how many photons per particle can be de-
tected. CPP values of ≥ 19 (488) and ≥ 11 (647) were pursued. With the measurement
of the calibrator solution the diﬀusion time (τdiff ) for both dyes was determined, as an
abnormal long diﬀusion time implies a diﬀuse focus. τdiff values of 180 ms for Alexa488
and 300 ms for Alexa647 were pursued. The measurement time for all samples was set to
10 sec.
4.6.3 Evaluation methods
For measurement analysis the programs FCS+_Evaluation 2.0, pooling_NTPs_2Dﬁda
and SIFT-2D (all Evotec) were available. These software packages allow diﬀerent data
evaluation:
FCS evaluation
Autocorrelation is a mathematical model to analyze noisy data. Noise is erased due to
its random appearance, whereas particles diﬀusing through the stationary focus lead to a
burst, an increase of the ﬂuorescent signal. The measurement time is divided into small
time windows of 50 ns, so called bins. Each bin can have the value 1 or 0 indicating if a
photon was collected at this time window or not. Each time window is multiplied with
another window of a certain distance, called correlation time. Correlation times vary from
50 ns (neighboring windows) up to the whole measurement time. The multiplications are
summed up for each correlation time, normalized and plotted as a curve on a logarithmic
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scale of the x-axis (Figure 4.1 A).In this way the autocorrelation allows a diﬀerentiation
between a randomly distributed signal (value 0 for large correlation times) and a burst
derived from a particle (value 1 for larger correlation times). With a mathematical ﬁt of
this curve (in Fig. 4.1 A depicted in red), a conclusion about up to four diﬀerent particle
species can be drawn. The quality of the ﬁt is given in the parameter chi2. Chi2 is depicted
in a residual curve, ideally randomly distributed around the x-axis (Fig. 4.1 B). τdiff is
deﬁned as the correlation time at which half the maximal value is reached. Fitting more
components gives the percentage of all molecules with a certain diﬀusion time. Details
about the particle concentration gives the total intensity (Itot) in kHz, directly derived
from the measurement of the APDs, whereas the particle number N is equivalent to the
inverse amplitude of the FCS curve after normalization.116 FCS evaluation was used for
reader adjustment (see section 4.6.2) and purity determination of labeled proteins (see
section 4.6.4).
BA
Figure 4.1: FCS curve of a pure dye solution A) Autocorrelation curve of the Alexa488 dye.
Logarithmic x-axis depicts the correlation times in ms, y-axis the sum over the multiplications for
each correlation time. B) Residual curve of the quality parameter chi2.
SIFT-2D
The SIFT-2D analysis is using the ﬂuorescence intensity distribution analysis (FIDA)
data from both channels and generates a 2D histogram with [photons/bin]488 on the
x-axis and [photons/bin]647 on the y-axis. The color-coded z-axis depicts the number
of events particles of speciﬁc size and color passing the focus. In this histogram small
monomeric particles are located at the origin, mono-colored multimers along the axes and
dual-colored multimers in the middle part of the histogram. For quantiﬁcation of the data,
the histogram is split into 9 equal segments and the photons per segment are summed up.
Mono-colored multimers, appearing at the histogram edge in segment 1 and 9, as well
as the monomeric fraction, within an appropriate threshold at the lower left corner, are
excluded from the quantiﬁcation. The number of highly intense bins is direct proportional
to the number of large aggregates. At the same time the composition of the aggregates
can be concluded from the the position of the dual-colored aggregates relative to the axes.
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Repeated measurements of the same sample (in one well) can be pooled with the
pooling_NTPs_2Dﬁda program.
4.6.4 Fluorescent protein labeling
Protein storage buﬀer:
50 mM Tris pH 7.5
For ﬂuorescent labeling, puriﬁed proteins (see section 4.5.4) were concentrated up to 100
M. For this purpose, Amicon Ultra-0.5 ml centrifugal ﬁlter devices (3 kDa cutoﬀ, Milli-
pore) were incubated for 2 h in H2Obidest with 1.4 % NP-40 at RT, washed with H2Obidest
and equilibrated with PBS. Proteins were thawed on ice and concentrated according to
the manufacturer’s protocol. Protein solution was divided into two equivalent volumes.
Fractions were labeled either with Alexa488 or Alexa647 (Table 4.16). Dyes were added at
3-fold excess in 100 mM sodium bicarbonate buﬀer (pH 8.5). Mix was incubated o/n at
4◦C. Afterward, unbound ﬂuorophores were removed by repeated gelﬁltration using Zeba
Spin Desalting Columns (Thermo Fisher) according to the manufacturer’s protocol until ≤
40% of the free dye was reached. Purity was checked with FCS measurements (see section
4.6.3). During gelﬁltration buﬀer was changed to 50 mM Tris buﬀer (pH 7.5). Labeling
eﬃciency was checked via proteinase K digestion to ensure equal load of ﬂuorophores for
all constructs. Protein samples were incubated with 200 g/ml proteinase K for 1 h at
37◦C. The increase of particles in the FCS measurement compared to the non-digested
sample is directly proportional to the label rate of the protein. Typical labeling rates were
3 ﬂuorophores/molecule. Proteins were aliquoted, frozen in liquid nitrogen and stored at
−80◦C.
Table 4.16: List of ﬂuorescent dyes. Dyes were dissolved in 100% DMSO
Abbreviation Dye Stock concentration Source
Alexa488 Alexa Fluor-488- 3.2 mM Molecular Probes (Eugene, USA)
O-Succinimidylester
Alexa647 Alexa Fluor-647- 1.6 mM Molecular Probes (Eugene, USA)
O-Succinimidylester
4.6.5 Incubation experiments
SIFT buﬀer: 50 mM Tris, 1 complete protease inhibitor cocktail EDTA-free tablet (Roche), 0.1% NaN3, pH 7.5,
Protein samples were thawed on ice, resuspended in 100 l SIFT buﬀer and centrifuged
at 60,000 g for 30 min at 4◦C. 70 l supernatant was transferred to a new LoBind tube.
Concentration of proteins were adjusted to an Itot of 1800 kHz (equivalent to ~80nM).
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Proteins labeled with Alexa488 (green) were mixed with an equal amount of proteins
labeled with Alexa647 (red). Samples were incubated at 37◦C shaking at 500 rpm. For
SIFT analysis at indicated time points, aliquots of the samples were diluted 1:7 into a 384-
well measurement plate and measured immediately with the Insight II Reader. Samples
were measured as triplicates with 5 repeats per well.
Synthetic compounds were selected from a compound library98 and were used with kind
permission of Armin Giese (Zentrum für Neuropathologie und Prionenforschung, Munich,
Germany). Natural polyphenolic compounds were obtaind as a kind gift from Neville
Vassallo (University of Malta)96. All compounds were stored in 100% DMSO and applied
to the sample in a ﬁnal concentration of 1% DMSO. Compounds were used at a ﬁnal
concentration of 10 M if not indicated diﬀerently.
4.6.6 Statistical analysis
Data generated with SIFT analysis were represented as mean values with SEM. Mann-
Whitney test was used for group statistics. For SIFT analysis of diﬀerent Notch3 variants
post hoc Wilcoxon signed-rank sum test with false discovery rate correction was used.
Signiﬁcance was indicated with asterisks: ∗ p<0.05; ∗∗ p<0.01; ∗∗∗ p<0.001
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